Clinical trial NCT03357731
Conditions: Heart Failure Cardiac Failure Reduced Ventricular Ejection Fraction
Sponsor: Bristol-Myers Squibb
Start date: 2017-11-30; Completion date: 2019-05-10
Enrollment: 49 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

Detailed description:

Arms: arm 1: administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods arm 2: administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods arm 3: administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods arm 4: administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods arm 5: administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods arm 6: administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Interventions: intervention 1: HNO Donor intervention 2: Nitroglycerin (NTG) intervention 3: Placebo
Intervention descriptions: intervention 1: Infusion intervention 2: Infusion intervention 3: Infusion

Protocol documents:
Prot_001.pdf: 
Page:
1
Protocol Number:
CV013020
IND Number:
118618
EUDRACT Number
2016-003586-26
Date
22-May-2017
Revised Date:
24-Jan-2019
CLINICAL PROTOCOL CV013020
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 
Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart 
Failure and Impaired Systolic Function
Revised Protocol: 05
Study Director
Medical Monitor
Maria Borentain MD
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (e.g., amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Revised Protocol No.: 05
Date: 24-Jan-2019
2
to partners to which BMS has transferred obligations, e.g., a Contract Research 
Organization (CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide 
a copy of this revised protocol to all study personnel under your supervision, and archive the 
previous versions.
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Revised Protocol No.: 05
Date: 24-Jan-2019
3
DOCUMENT HISTORY
Document
Date of Issue
Summary of Change
Revised Protocol 05
24-Jan-2019
Clarified the wording the Appendix 3 to harmonize AE definitions in 
BMS clinical studies. Clarified the enrollment numbers under study 
drug.
Revised Protocol 04
05-Sep-2018
Incorporating Administrative Letters 03 and 04 content that was not 
included in Revised Protocol 03
Revised Protocol 03
17-Jul-2018
 
 
Administrative 
Letter 04
02-Feb-2018
To clarify the origin of Nitroglycerin supplied by BMS. 
Administrative 
Letter 03
26-Oct-2017
Correct minor typographical errors identified throughout the protocol.
Revised Protocol 02
01-Sep-2017
Clarification of allowable contraceptives for WOCBP, addition of 
chronic nitrates use criteria, clarification of IP preparation, handling and 
storage
Administrative 
Letter 02
12-Jul-2017
Clarification of IP formulation as vials or ampules. 
Administrative 
Letter 01
05-Jul-2017
Clarification of follow-up phone call 30 days after the end of the 
infusion of the last period (will assess occurrence of any SAEs)
Revised Protocol 01
14-Jun-2017
Inserted additional text into Section 8.1: ‘Discontinuation from Study 
Treatment’ to allow the patient to be part of the IP continuation 
discussion when confirmed pregnant. 
Original Protocol
22-May-2017
Not Applicable
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
OVERALL RATIONALE FOR REVISED PROTOCOL 05:
The rational for updating this protocol is that the current version of Appendix 3 directs that disease-
related events do not meet the AE definition and, therefore, should not be reported as AEs. The 
update is part of a larger effort to harmonize AE definitions in BMS clinical studies and more 
particularly to allow reporting of any type of disease-related events.
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 05
Section Number 
& Title
Description of Change
Brief Rationale
Appendix 3
Updated Appendix 3 to 
clarify the collection of 
disease related events.
The current version directs that disease-related events do not 
meet the AE definition and, therefore, should not be reported as 
AEs. 
Unnecessary text was deleted to clarify that disease related 
events and events associated with lack of efficacy will need to 
continue to be reported as AEs if the event meets the criteria of 
an AE while text was added to clarify the need to report 
abnormal lab tests or other safety assessments when the final 
diagnosis is not available.
Content was added to clarify the need for the investigator to 
report the specific term of “intentional overdose” as an AE 
term.
The change is part of a larger effort to harmonize AE 
definitions in BMS clinical studies and more particularly to 
allow reporting of any type of disease-related events.
Summary
Clarified the enrollment 
numbers were 
approximately 42 
participants
Brought the enrollment number estimates to align with other 
sections of the protocol.
Section 5.1
Clarified the enrollment 
numbers were 
approximately 42 
participants
Brought the enrollment number estimates to align with other 
sections of the protocol.
Section 9.4.4
Corrected to 
inclusion/exclusion 
criteria
Corrected a typographical error from the incorporation of 
Administrative Letter 03 during Revised Protocol 04
Revised Protocol No.: 05
Date: 24-Jan-2019
4
6.0
Approved
930114837
6.0
v


TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. 
OVERALL RATIONALE FOR REVISED PROTOCOL 05: ..................................... 
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 05 ......................... 
TABLE OF CONTENTS .............................................................................................. 
1 SYNOPSIS ................................................................................................................. 
2 SCHEDULE OF ACTIVITIES.................................................................................. 
3 INTRODUCTION ..................................................................................................... 
 
 
 
4 OBJECTIVES AND ENDPOINTS ........................................................................... 
5 STUDY DESIGN....................................................................................................... 
5.1 Overall Design .................................................................................................. 
5.1.1 Data Monitoring Committee and Other External Committees ................ 
5.2 Number of Participants ..................................................................................... 
5.3 End of Study Definition .................................................................................... 
 
 
6 STUDY POPULATION ............................................................................................ 
6.1 Inclusion Criteria .............................................................................................. 
6.2 Exclusion Criteria ............................................................................................. 
6.3 Lifestyle Restrictions ........................................................................................ 
6.4 Screen Failures .................................................................................................. 
6.4.1 Retesting During Screening or Lead-In Period ....................................... 
7 TREATMENT ........................................................................................................... 
7.1 Treatments Administered .................................................................................. 
7.2 Method of Treatment Assignment .................................................................... 
7.3 Blinding............................................................................................................. 
7.3.1 Emergency Unblinding ............................................................................ 
7.3.2 Other Blinding and Unblinding ............................................................... 
7.4 Dosage Modification ......................................................................................... 
7.5 Preparation/Handling/Storage/Accountability .................................................. 
7.5.1 Retained Samples for Bioavailability / Bioequivalence ........................... 
7.6 Treatment Compliance ...................................................................................... 
7.7 Concomitant Therapy........................................................................................ 
7.7.1 Prohibited and/or Restricted Treatments................................................. 
7.7.2 Other Restrictions and Precautions ......................................................... 
7.7.2.1 Imaging Restriction and Precautions ............................................. 
7.8 Treatment After the End of the Study ............................................................... 
8 DISCONTINUATION CRITERIA ........................................................................... 
8.1 Discontinuation from Study Treatment ............................................................ 
8.1.1 Post Study Treatment Study Follow-up.................................................... 
8.2 Discontinuation from the Study ........................................................................ 
1
3
4
4
5
8
16
21
27
28
28
30
30
31
33
33
34
36
36
36
37
39
39
39
39
40
40
42
42
42
42
42
43
43
43
43
43
44
44
Clinical Protocol
BMS-986231
CV013020
HNO Donor
Revised Protocol No.: 05
Date: 24-Jan-2019
5
6.0
Approved
930114837
6.0
v


8.3 Lost to Follow-Up ............................................................................................. 
9 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
9.1 Efficacy Assessments ........................................................................................ 
9.1.1 Imaging Assessment for the Study............................................................ 
9.2 Adverse Events ................................................................................................. 
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
9.2.5 Pregnancy ................................................................................................ 
9.2.6 Laboratory Test Result Abnormalities ..................................................... 
9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................ 
9.2.8 Other Safety Considerations .................................................................... 
9.3 Overdose ........................................................................................................... 
9.4 Safety ................................................................................................................ 
9.4.1 Physical Examinations ............................................................................. 
9.4.2 Vital signs................................................................................................. 
9.4.3 Electrocardiograms ................................................................................. 
9.4.4 Clinical Safety Laboratory Assessments .................................................. 
9.4.5 Suicidal Risk Monitoring ......................................................................... 
9.4.6 Imaging Safety Assessment ...................................................................... 
9.5 Pharmacokinetic Assessments .......................................................................... 
9.6 Pharmacodynamics ........................................................................................... 
9.7 Pharmacogenomics ........................................................................................... 
9.7.1 ADME Sampling ...................................................................................... 
 
 
 
 
 
 
 
 
9.9 Health Economics OR Medical Resource Utilization and Health Economics . 
10 STATISTICAL CONSIDERATIONS .................................................................... 
10.1 Sample Size Determination ............................................................................. 
10.2 Populations for Analyses ................................................................................ 
10.3 Statistical Analyses ......................................................................................... 
10.3.1 Efficacy Analyses ................................................................................... 
10.3.2 Safety Analyses....................................................................................... 
10.3.3 Other Analyses ....................................................................................... 
10.3.4 Pharmacokinetic Analyses ..................................................................... 
10.3.5 Interim Analyses ..................................................................................... 
 
12 APPENDICES ......................................................................................................... 
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ........................................ 
45
45
46
46
46
47
48
48
48
48
49
49
50
50
50
50
50
51
51
53
53
53
54
54
54
55
55
55
56
56
57
57
57
57
57
62
63
Clinical Protocol
BMS-986231
CV013020
HNO Donor
Revised Protocol No.: 05
Date: 24-Jan-2019
6
6.0
Approved
930114837
6.0
v


APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS ................................. 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING ......................................................................... 
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ..................................................................... 
 
66
73
78
Clinical Protocol
BMS-986231
CV013020
HNO Donor
Revised Protocol No.: 05
Date: 24-Jan-2019
7
6.0
Approved
930114837
6.0
v








Clinical Protocol
CV013020
BMS-986231
HNO Donor
Objectives and Endpoints:
Table 1-1:
Objectives and Endpoints
Objectives
Endpoints
Primary
• Evaluate the effects of BMS-986231 on the left 
ventricular (LV) systolic function by stroke volume 
index (SVI) assessed by echocardiography compared 
to placebo.
• Mean SVI derived from the velocity time 
integral at the left ventricular outflow tract 
(LVOT VTI) at the end of the 5-hours infusion 
of BMS-986231, versus placebo.
Secondary
• Evaluate the effects of BMS-986231 on the left 
ventricular (LV) systolic function by stroke volume 
index (SVI) assessed by echocardiography compared 
to nitroglycerin (NTG).
• Evaluate the effects of BMS-986231 on selected 
other left ventricular systolic and diastolic indices 
compared to placebo and NTG
•
Mean SVI derived from LVOT VTI at the end of 
the 5-hours infusion of BMS-986231, versus 
NTG.
•
Mean LVEF, computed by Simpson’s method at 
the end of the 5-hours infusion of BMS-986231, 
versus placebo and NTG.
•
Mean cardiac power index at the end of the 5-
hours infusion of BMS-986231, versus placebo 
and NTG. 
•
Mean Diastolic indices: E/A, annular e' velocity 
and E/e' ratio at the end of the 5-hours infusion of 
BMS-986231, versus placebo and NTG.
•
Mean LV global longitudinal strain, computed 
using STE at the end of the 5-hours infusion of 
BMS-986231, versus placebo and NTG.
Overall Design:
This is a multi-center, randomized, cross-over, placebo and active-controlled, double-blind, study 
of continuous 5-hour intravenous (IV) infusion of BMS-986231 in patients with heart failure and 
reduced ejection fraction (HFrEF). The trial is designed to evaluate the effects of BMS-986231on 
systolic and diastolic parameters measured by echocardiography.
Design
A cross-over design will be implemented in this trial, every subject will be exposed to each of the 
3 interventions in 3 treatment periods (BMS-986231, NTG and placebo) with one intervention 
occurring during each treatment period, including the 5-hour infusion, followed by a washout 
period of at least 5 days, but no more than 4 weeks. 
Study drug
Approximately 42 study participants will be randomized to receive BMS-986231, NTG, and 
placebo, in one of the 6 possible sequences.
NTG, BMS-986231 and placebo: will be administered as a 5-hours infusion according to an up-
titration schedule, which is achieved by an increase in the infusion flow rate. All three interventions 
Revised Protocol No.: 05
Date: 24-Jan-2019
11
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
(NTG, BMS-986231 and placebo) will have the same flow rate as follows: 5 mL/H for 10 min, 
followed by 10 mL/H for 10 minutes then 20 mL/H for the rest of the infusion.
The corresponding doses of the active study medications will be:
•
NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for the 
rest of the 5-hour infusion; 
•
BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 
12 μg/kg/min for the rest of the 5-hour infusion.
In case of decrease in systolic blood pressure, an algorithm will be used to down-titrate / interrupt 
or discontinue the study drug infusion (see section 7.4 in the protocol).
Screening
Screening for inclusion in the study will be performed up to 4 weeks before the first treatment day. 
Screening will assess the eligibility criteria including assessment of ejection fraction, suitability of 
echocardiography windows and image quality. After screening, study participants will be enrolled 
in the study according to their eligibility as per the inclusion and exclusion criteria, and will be 
randomized to 1 of the 6 sequences that will be conducted in parallel.
If the period 1 treatment day could only be scheduled beyond 4 weeks from screening, a 
consultation with the medical monitor is needed to identify which screening procedure should be 
repeated prior to randomization.
Treatment day (Day 1 of each period)
Study participants will be admitted to the study facility on the treatment day, which will be the 
Day 1 of each of the three periods. Assessment of vital signs and laboratory tests will be performed 
pre-dose. In each treatment day, blood pressure and heart rate should be within the inclusion / 
exclusion criteria limits, and no atrial fibrillation or atrial flutter should be present in order to start 
the study treatment. The study drug infusion could start without waiting for the results of the 
laboratory assessments done in the morning of the treatment day at the study facility if the 
following criteria are met:
•
The results of the laboratory assessment at screening / previous period are within ranges 
compatible with inclusion/exclusion criteria, 
•
The study participant was medically stable without change in medication since the screening 
visit / previous period. 
If the laboratory tests (e.g. electrolytes, serum creatinine, eGFR, hemoglobin, transaminases) prior
to infusion, are not within inclusion and exclusion criteria limits, the study drug will be 
discontinued after consultation with the medical monitor. The abnormalities should be corrected 
before the next treatment period. 
Physical examinations, vital sign measurements, 12-lead electrocardiograms (ECG), 
echocardiography, whole body bioimpedance and pulse wave analysis (non-invasive central aortic 
blood pressure) will be performed at selected times throughout the dosing interval. Participants 
Revised Protocol No.: 05
Date: 24-Jan-2019
12
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
will be closely monitored for adverse events throughout the study. Blood samples will also be 
collected at selected intervals after the start of study drug administration for pharmacokinetic (PK) 
analysis.
Discharge
Study participants will remain in the study facility for approximately 3.5 hours post-dose and 
discharged on the same day, unless the investigator and the study team consider that an overnight 
stay is warranted. Same-day discharge is allowed if the following conditions are met:
•
in the opinion of the investigator an overnight stay is not warranted, 
•
there is no hypotension after mobilization and 
•
none of the following events occurred during the study drug infusion: prolonged hypotension, 
symptoms of hypotension, new onset of sustained arrhythmia requiring pharmacologic or other 
interventions, any other events of concern e.g. chest pain suggestive of ischemia.
Figure 1: 
Study design
Number of Participants: 
Sample sizes are calculated based on comparison of post-baseline values, adjusting for the 
differences in the baseline value.  Sample size calculations assume an increase of the stroke volume 
index (SVI) of 4.5 mL/m² from baseline, relative to placebo, an inter-individual SD of 10 mL/m², 
*Wash-out period will be at least 5 days, but no more than 4 weeks.
Revised Protocol No.: 05
Date: 24-Jan-2019
13
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
and intra-individual correlations for the difference between assessments of 0.7. Approximately 36 
subjects with data from treatment periods being compared will be required to achieve a power of 
90%, with a type I error probability of 0.05 (2-sided).  In order to address the potential for missing 
data arising from withdrawal from the study, an allowance of approximately 15% subjects will be 
included, with a resulting target sample size of 42 subjects to be randomized. An estimated 42 
subjects will be randomized, in order to complete 36 subjects.
Randomized:  42
Key Inclusion / Exclusion Criteria:  
Inclusion:
•
Signed Written Informed Consent
•
Age 18 years (or age of majority) or older
•
Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less), as 
assessed by the echocardiographic core lab.
•
Stable guideline directed therapy for heart failure (could include oral diuretics, ACEi, ARBs, 
ARNi, MRAs , and β blockers as tolerated), with no dose changes of these medications in the 
past 2 weeks
•
Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10
pmol/L).
•
In sinus rhythm at the start of the infusion
Exclusion:
•
Body weight < 45 kg or  ≥ 140 kg
•
Low quality echocardiographic visualization windows and image acquisition
•
Systolic blood pressure (SBP) < 110 mm Hg at screening or pre-randomization 
•
Heart rate < 50 beats per minute (bpm) or > 90 bpm at screening or pre-randomization 
•
Permanent Atrial Fibrillation, Atrial  Flutter or having Atrial Fibrillation, Atrial  Flutter before 
start of the infusion
•
Permanent paced rhythm (VVI, DDD or BiV pacing)
•
Ventricular assist device or prior heart transplant
•
Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic 
hypertrophic or uncorrected severe valvular disease as defined by AHA/ACC/ESC criteria.
•
(Note: A restrictive mitral inflow pattern is NOT exclusionary)
•
Large post-MI Left Ventricular aneurisms 
•
Intra-cardiac thrombus
•
Prior mitral valve repair, mitral or aortic prosthesis
Revised Protocol No.: 05
Date: 24-Jan-2019
14
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Treatment with oral phosphodiesterase type 5 (PDE5) inhibitor sildenafil, vardenafil or 
avanafil within 24 hours of study drug infusion or treated with tadalafil within 4 days of study 
drug infusion 
•
Hospitalized for acute decompensated heart failure in the previous month
•
Hospitalized with acute coronary syndrome, coronary revascularization or acute myocardial 
infarction during the previous 90 days prior to screening
•
Have a history of a cerebral vascular accident (CVA or stroke) or of a transient ischemic attack 
(TIA) during the previous 90 days prior to screening
•
NYHA Class IV symptoms of heart failure
•
Treatment with intravenous inotropic therapy (dobutamine, milrinone, levosimendan) in the 
previous month or planned treatment in the next 3 months.
•
Current treatment with chronic oral, transdermal or sublingual nitrates, except at the discretion 
of the investigator and treating physician, nitrates could be temporarily interrupted.  In which
case, an interruption of 3 days is required prior to start of study drug.
•
Prior solid organ transplant 
•
Estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m2
•
Have persistent abnormal serum electrolytes not resolved between screening and start of the 
study drug infusion, as defined by any of the following:
o
A sodium (Na+) concentration < 130 or >145 mEq/L (mmol/L)
o
A potassium (K+) concentration < 3.2 or >5.5 mEq/L (mmol/L)
•
Have severe anemia, as documented by a hemoglobin < 9 g/dL (< 5.59 mmol/L)
•
Liver disease defined as history of cirrhosis with evidence of portal hypertension such as 
varices, or encephalopathy, or total bilirubin > 3 mg/dL (> 51 μmol/L) or significant elevation 
of liver enzymes (AST, ALT > 3 times the upper limit of normal)
•
Considered clinically unstable for any condition
•
Serious comorbid non cardiovascular disease in which the life expectancy of the subject is < 3 
months
•
Known hypersensitivity or contra-indication to the intravenous echocardiography contrast 
agent, in case contrast echocardiography is used
Revised Protocol No.: 05
Date: 24-Jan-2019
15
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
2
SCHEDULE OF ACTIVITIES
Table 2.-1:
Time & Event Schedule CV013020, Screening Period
Procedure 
Screening Visit
Notes
Eligibility Assessments
Informed Consent
x
A participant is considered enrolled only when a 
protocol specific informed consent is signed.
Inclusion/Exclusion Criteria
x
Medical History
x
Concomitant medications
x
Echocardiography eligibility assessment
x
As described in the echocardiographic core lab 
manual,
evaluation 
of 
image 
quality 
and 
assessment of ejection fraction
Safety Assessments
Physical Examination
x
If the screening physical examination is performed 
within 3 days prior to first dosing then a single 
exam may count as both the screening and pre-
dose evaluation.
Includes height and weight.
Vital Signs
x
Includes body temperature, respiratory rate, and 
seated blood pressure and heart rate. Blood 
pressure and heart rate should be measured after 
the participant has been resting quietly for at least 
5 minutes.
Adverse Events Assessment
x
SAEs must be collected from the date of the 
participant’s Informed consent.
Local Laboratory Tests
x
Hematology, Serum chemistry, NT-proBNP or 
BNP (details in the protocol section 9.4.4)
Pregnancy Test 
(WOCBP only)
x
Revised Protocol No.: 05
Date: 24-Jan-2019
16
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Table 2.-2:
Time & Event Schedule CV013020, Treatment and Follow-up Study Periods
Procedure
Treatment Period
Notes
Period 1
Day 1
Washout 
5-28 
Days
Period 2
Day 1
Washout
5-28 
Days
Period 3
Day 1
Washout between periods should be at least 5 days 
and no more than 4 weeks.
Safety Assessments
Weight
x
x
x
Weight pre-and end of the infusion in each treatment 
period.
Targeted physical examination
x
x
x
Based on subject’s report since the screening visit. 
Includes temperature, signs and symptoms of 
congestion.
Vital Signs 
(Blood pressure and heart rate)
x
x
x
Prior to infusion. 30 minutes at first hour, then every 1 
hour until discontinuation of infusion, then at 1 hour, 
2 hour and 3.5 hour after end of infusion in each 
treatment period .
Peripheral Oxygen Saturation
x
x
x
Prior and end of the infusion in each treatment period, 
measured with a pulse oximeter device.
12 lead ECG
x
x
x
Prior to the infusion and after end of infusion in each 
treatment period.
Urinary output
x
x
x
From start of infusion to 3 hours after end of infusion 
in each treatment period.
Telemetry
x
x
x
From start of infusion to 3 hours after end of infusion 
in each treatment period.
Adverse Events Assessment
x
x
x
Non-serious AEs will be collected from the start of 
the study drug infusion. until 24 hours after end of 
infusion in each treatment period of dosing in each 
period
Serious adverse events must be collected from the 
date of Informed consent and will be assessed up to 
30 days after the end of infusion of the last period.
Revised Protocol No.: 05
Date: 24-Jan-2019
17
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Table 2.-2:
Time & Event Schedule CV013020, Treatment and Follow-up Study Periods
Procedure
Treatment Period
Notes
Period 1
Day 1
Washout 
5-28 
Days
Period 2
Day 1
Washout
5-28 
Days
Period 3
Day 1
Washout between periods should be at least 5 days 
and no more than 4 weeks.
Concomitant Medications
x
x
x
Chronic heart failure medications to be taken during 
the treatment day (D1 of each period) will be withheld 
until the end of the study drug infusion in each 
treatment period.
Follow-up call
x
x
x
Follow-up call to be done at Day 2 of each
period (will inquire about general status
and occurrence of any AEs) and 30 days
after the end of the infusion of the last
period (will assess occurrence of any
SAEs).
Local Laboratory Tests
x
x
x
Hematology and Serum chemistry (details in the 
protocol section 9.4.4).  Can be performed within 24 
hours of treatment day.
Central Laboratory Tests
x
x
x
Hematology, 
Serum 
chemistry, 
Urinalysis, 
Biomarkers (details in the protocol section 9.4.4)
Pharmacokinetic (PK) sampling
x
x
x
PK sampling will be done pre-dose, 0.5 hour, 1 hour, 
4.5 hours and 7 hours after the start of the infusion in 
each treatment period.
In addition, PK samples should be taken when the 
dose is lowered or in case of early discontinuation 
(see protocol section 9.5)
Pregnancy Test (WOCBP only)
x
x
x
Can be performed within 24 hours of treatment day.
Efficacy Assessments
Echocardiography
x
x
x
Prior to and before the end of the study infusion 
(between hour 4 and hour 5) in each treatment period.
If study drug is interrupted prematurely, the 
echocardiography assessment should be done as soon 
Revised Protocol No.: 05
Date: 24-Jan-2019
18
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Table 2.-2:
Time & Event Schedule CV013020, Treatment and Follow-up Study Periods
Procedure
Treatment Period
Notes
Period 1
Day 1
Washout 
5-28 
Days
Period 2
Day 1
Washout
5-28 
Days
Period 3
Day 1
Washout between periods should be at least 5 days 
and no more than 4 weeks.
as possible after study drug interruption. 
If the study drug is resumed after interruption, 
echocardiography should be repeated between hour 4 
and hour 5 of the effective study drug infusion.
Whole body bioimpedance
x
x
x
Prior to infusion, at 1 hour and 3 hours after start of 
infusion, at end of infusion and 2 hours after the end 
of the infusion in each treatment period.
In addition, should be performed after each 
supplementary echocardiographic assessment.
Pulse wave analysis
x
x
x
Prior to and at end of infusion in each treatment 
period, just after the echocardiographic assessment 
has been performed. In addition, should be performed 
after 
each 
supplementary 
echocardiographic 
assessment.
Administer Study Medication
x
x
x
5-hour continuous infusion
Study medication to begin promptly after pre-
infusion testing completed
Clinical Drug Supplies
Randomize
x
Dispense Study Drug
x
x
x
Additional Research Sampling
Additional Research plasma
x
x
x
Sampling will be done pre-dose and 4.5 hours after 
the start of the infusion in each treatment period.
Blood sampling for DNA variants in 
mARC and ADME related genes
x
Sample can be collected at Period 1 Day1 or any other 
day, only one sample collection for each subject 
during the study.
In the event of multiple procedures are required at a single time point, the following order for performing the procedures is recommended:
Revised Protocol No.: 05
Date: 24-Jan-2019
19
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Safety
•
Pharmacokinetic sampling
•
Additional research sampling
Revised Protocol No.: 05
Date: 24-Jan-2019
20
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
3
INTRODUCTION
Heart failure is a leading cause of morbidity and mortality. Acute decompensated heart failure 
(ADHF) is the number one cause of hospitalization in the elderly, and is associated with 
considerable morbidity, mortality and economic cost1,2. Although advances in drug and device 
treatment of chronic heart failure over the past 40 years have led to improvements in outcome of 
these patients, the morbidity and mortality of heart failure remains high. In contrast, there have 
been few advances in the approach to treat episodes of acute decompensated heart failure 
(ADHF) over the same time period, and no therapies have been demonstrated to improve long-
term clinical outcomes3.
Standard of care therapies for ADHF are based on the use of intravenous diuretics to promote 
fluid removal to reduce dyspnea, and in some patients, oral or intravenous vasodilators, to reduce 
the load on the heart and improve cardiac performance4. Collectively, these treatments may 
reduce dyspnea but do not target the primary cause of heart failure, impaired cardiac 
contractility. Drugs that specifically enhance diminished cardiac contractility, called inotropic 
agents, may have an important role to help rapidly improve hemodynamics leading to rapid 
symptom relief. However the use of currently available cardiac inotropic drugs is associated with 
increased heart rate and myocardial oxygen consumption, induction of atrial and ventricular 
arrhythmias, concerns about provocation of ischemia, and adverse long-term outcomes, limiting 
the use of these inotropic agents to low cardiac output state with signs of end-organ 
hypoperfusion5,6,7. 
An agent that increases contractility, while avoiding the adverse safety profile of an inotropic 
agent and retaining the capacity to unloading the heart, could address a significant unmet 
medical need and be used in a broader patient population. 
In this context, BMS-986231, a second generation HNO donor, it’s being developed in ADHF. It 
has demonstrated vasodilation, enhanced inotropy and improved relaxation in animal models and 
improved hemodynamics consistent with vasodilation and inotropic effect in early studies in 
humans. 
A study to characterize the cardiac effects of BMS-986231 on systolic and diastolic function will 
enhance the understanding of the mechanism of action of HNO, and better delineate the relative 
contributions of vasodilation, enhanced contractility, and improved relaxation on the effects of 
BMS-986231 on cardiac function. Such a mechanistic study may help inform future 
development by demonstrating a differentiated effect compared to nitro-vasodilators which do 
not enhance either cardiac contractility and or relaxation.
 
 
 
 
 
 
  
 
 
Revised Protocol No.: 05
Date: 24-Jan-2019
21
6.0
Approved
930114837
6.0
v












Clinical Protocol
CV013020
BMS-986231
HNO Donor
 
4
OBJECTIVES AND ENDPOINTS
Table 4.-1:
Objectives and Endpoints
Objectives
Endpoints
Primary
Evaluate the effects of BMS-986231 on the left 
ventricular (LV) systolic function by stroke volume 
index (SVI) assessed by echocardiography compared to 
placebo.
Mean SVI derived from the velocity time integral at 
the left ventricular outflow tract (LVOT VTI) at the 
end of the 5-hours infusion of BMS-986231, versus 
placebo.
Secondary
Evaluate the effects of BMS-986231 on the left 
ventricular (LV) systolic function by stroke volume 
index (SVI) assessed by echocardiography compared to 
nitroglycerin (NTG).
Mean SVI derived from LVOT VTI at the end of the 5-
hours infusion of BMS-986231, versus NTG.
Evaluate the effects of BMS-986231 on selected other 
left ventricular systolic and diastolic indices compared 
to placebo and NTG:
LV ejection fraction
Mean LV power index
Diastolic function
LV global longitudinal strain
Mean LVEF, computed by Simpson’s method at the 
end of the 5-hours infusion of BMS-986231, versus 
placebo and NTG.
Mean cardiac power index at the end of the 5-hours 
infusion of BMS-986231, versus placebo and NTG. 
Mean Diastolic indices: E/A, annular e’ velocity, and 
E/e’ ratio at the end of the 5-hours infusion of BMS-
986231, versus placebo and NTG. 
Mean LV global longitudinal strain, computed using 
STE at the end of the 5-hours infusion of BMS-
986231, versus placebo and NTG.
Revised Protocol No.: 05
Date: 24-Jan-2019
27
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Table 4.-1:
Objectives and Endpoints
5
STUDY DESIGN
5.1
Overall Design
This is a multi-center, randomized, cross-over, placebo and active-controlled, double-blind, 
study of continuous 5-hour intravenous (IV) infusions of BMS-986231 in patients with heart 
failure and reduced ejection fraction (HFrEF). The trial is designed to evaluate the effects of 
BMS-986231on systolic and diastolic parameters measured by echocardiography.
Design
A cross-over design will be implemented in this trial, every subject will be exposed to each of 
the 3 interventions in 3 treatment periods (BMS-986231, NTG and placebo) with one 
intervention occurring during each treatment period, including the 5-hour infusion, followed by a 
washout period of at least 5 days, but no more than 4 weeks. 
Study drug
Approximately 42 study participants will be randomized to receive BMS-986231, NTG, and 
placebo, in one of the 6 possible sequences.
NTG, BMS-986231 and placebo will be administered as a 5-hours infusion, according to an up-
titration schedule, which is achieved by an increase in the infusion flow rate. All three 
interventions (NTG, BMS-986231 and placebo) will have the same flow rate as follows: 5 mL/H 
for 10 min, followed by 10 mL/H for 10 minutes then 20 mL/H for the rest of the infusion.
The corresponding doses of the active study medications will be:
•
NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for 
the rest of the 5-hour infusion; 
•
BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 
12 μg/kg/min for the rest of the 5-hour infusion. 
Revised Protocol No.: 05
Date: 24-Jan-2019
28
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
In case of a decrease in systolic blood pressure, an algorithm will be used to down-titrate / 
interrupt or discontinue the study drug infusion (see section 7.4 in the protocol).
Screening
Screening for inclusion in the study will be performed up to 4 weeks before the first treatment 
day. Screening will assess the eligibility criteria including assessment of ejection fraction, 
suitability of echocardiography windows and image quality. After screening, study participants 
will be enrolled in the study according to their eligibility as per the inclusion and exclusion 
criteria, and will be randomized to 1 of the 6 sequences that will be conducted in parallel.
If the first period of treatment day could only be scheduled beyond 4 weeks from screening, a 
consultation with the BMS/PPD medical monitor is needed to identify which screening 
procedure should be repeated prior to randomization.
Treatment day (Day 1 of each period)
Study participants will be admitted to the study facility on the treatment day, which will be the 
Day 1 of each of the three periods. Assessment of vital signs and laboratory tests will be
performed pre-dose. In each treatment day, blood pressure and heart rate should be within the 
inclusion / exclusion criteria limits, and no atrial fibrillation or atrial flutter should be present in 
order to start the study treatment. The study drug infusion could start without waiting for the 
results of the laboratory assessments done in the morning of the treatment day at the study 
facility if the following criteria are met:
•
The results of the laboratory assessment at screening / previous period are within ranges 
compatible with inclusion/exclusion criteria, 
•
The study participant was medically stable without change in medication since the screening 
visit / previous period. 
If the laboratory tests (e.g. electrolytes, serum creatinine, eGFR, hemoglobin, transaminases) 
prior to the infusion, are not within inclusion and exclusion criteria limits, the study drug will be 
discontinued after consultation with the medical monitor. The abnormalities should be corrected 
before the next treatment period. 
Physical
examinations, vital sign measurements, 12-lead electrocardiograms (ECG), 
echocardiography, whole body bioimpedance and pulse wave analysis (non-invasive central 
aortic blood pressure) will be performed at selected times throughout the dosing interval. 
Participants will be closely monitored for adverse events throughout the study. Blood samples 
will also be collected at selected intervals after start of study drug administration for 
pharmacokinetic (PK) analysis.
Discharge
Study participants will remain in the study facility for approximately 3.5 hours post-dose and 
discharged on the same day, unless the investigator and the study team consider that an overnight 
stay is warranted. Same-day discharge is allowed if the following conditions are met:
•
in the opinion of the investigator an overnight stay is not warranted, 
•
there is no hypotension after mobilization and 
Revised Protocol No.: 05
Date: 24-Jan-2019
29
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
none of the following events occurred during the study drug infusion: prolonged 
hypotension, symptoms of hypotension, new onset of sustained arrhythmia requiring 
pharmacologic or other interventions, any other events of concern e.g. chest pain suggestive 
of ischemia.
The study design schematic is presented in Figure 5.1-1
Figure 5.1-1:
Study Design Schematic
5.1.1
Data Monitoring Committee and Other External Committees
There is no Data Monitoring Committee (DMC) planned for this study. Occurrence of significant 
safety events will be submitted for review to the independent DMC that monitors the ongoing 
phase 2b study, evaluating the safety, tolerability and effectiveness of BMS-986231 in a 
population of acute decompensated heart failure patients (NCT03016325)25.  
The executive committee will be a small body comprised of academic leaders. The executive 
committee will provide advice on overall design, study endpoints and recommendations for 
study sites, and will review results from final analyses with Sponsor.
5.2
Number of Participants
Sample size calculations assume an increase of the stroke volume index (SVI) of 4.5 mL/m² 
from baseline, relative to placebo, an inter-individual SD of 10 mL/m², and intra-individual 
correlations for the difference between assessments of 0.7. Approximately 36 subjects with data 
from treatment periods being compared will be required to achieve a power of 90%, with a type I 
* Was-out period will be at least 5 days, but no more than 4 weeks.
Revised Protocol No.: 05
Date: 24-Jan-2019
30
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
error probability of 0.05 (2-sided).  In order to address the potential for missing data arising from 
withdrawal from the study and/or losses to follow-up, an allowance of approximately 15% 
subjects will be included, with a resulting target sample size of 42 subjects to be randomized.
An estimated 42 subjects will be randomized, in order to complete the study with 36 subjects. 
Further details are provided in Section 10.
5.3
End of Study Definition
The start of the trial is defined as the first visit for the first participant screened. End of trial is 
defined as the last visit or scheduled procedure shown in Section 2, the Schedule of Activities, 
for the last participant. Study completion is defined as the final date on which data for the 
primary endpoint was or is expected to be collected.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 05
Date: 24-Jan-2019
31
6.0
Approved
930114837
6.0
v




Clinical Protocol
CV013020
BMS-986231
HNO Donor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
STUDY POPULATION
For entry into the study, the following criteria MUST be met.
6.1
Inclusion Criteria
1) Signed Written Informed Consent
a) Subjects will be required to provide a written informed consent.
Revised Protocol No.: 05
Date: 24-Jan-2019
33
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
2) Type of Participant and Target Disease Characteristics
a) Males and Females, ages 18 (or age of majority) or older 
b) Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less)
c) Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, 
ARNi, MRAs , and β blockers as tolerated), with no dose changes of these medications in 
the past 2 weeks
d) Have screening values of NT pro-BNP ≥125 pg/mL (15 pmol/L) or BNP ≥35 pg/mL
(10 pmol/L).
e) In sinus rhythm at the start of the infusion
3) Age and Reproductive Status
a) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 
24 hours prior to the start of study treatment.
b) Women must not be breastfeeding
c) Women of childbearing potential (WOCBP) must agree to follow instructions for 
methods of contraception for 32 days after discontinuation (duration of study drug plus 
30 days duration of one ovulatory cycle).
d) Males who are sexually active with WOCBP must agree to follow instructions for 
methods of contraception (Appendix 4) for total of 91 days after discontinuation 
(duration of study drug plus 90 days [duration of sperm turnover]).
e) Azoospermic males are exempt from contraceptive requirements. WOCBP who are 
continuously not heterosexually active are also exempt from contraceptive requirements, 
but still must undergo pregnancy testing as described in this section.
Investigators shall counsel WOCBP, and male participants who are sexually active with 
WOCBP, on the importance of pregnancy prevention and the implications of an unexpected 
pregnancy. Investigators shall advise on the use of highly effective methods of contraception, 
(Appendix 4) which have a failure rate of < 1% when used consistently and correctly.
Local laws and regulations may require use of alternative and/or additional contraception 
methods.
6.2
Exclusion Criteria
1) Target Disease Exceptions
a) Systolic blood pressure (SBP) < 110 mm Hg at screening or pre-randomization
b) Heart rate < 50 beats per minute (bpm) or > 90 bpm at screening orpre-randomization 
c) Permanent Atrial Fibrillation, Atrial  Flutter or having Atrial Fibrillation, Atrial Flutter 
before start of the infusion
d) Permanent paced rhythm (VVI, DDD or BiV pacing)
e) NYHA Class IV symptoms of heart failure
Revised Protocol No.: 05
Date: 24-Jan-2019
34
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
2) Medical History and Concurrent Disease
a) Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, 
idiopathic hypertrophic or uncorrected severe valvular disease as defined by 
AHA/ACC/ESC criteria. (Note: A restrictive mitral inflow pattern is not exclusionary)
b) Pericardial tamponade or constrictive pericarditis
c) Large post-MI LV aneurisms 
d) Intra-cardiac thrombus
e) Prior mitral valve repair, mitral or aortic prosthesis of any type.
f)
LV assist device or prior heart transplant
g) Hospitalized for acute decompensated heart failure in the previous month
h) Hospitalized with acute coronary syndrome, coronary revascularization or acute 
myocardial infarction during the previous 90 days prior to screening
i)
Have a history of a cerebral vascular accident (CVA or stroke) or of a transient ischemic 
attack (TIA) during the previous 90 days prior to screening
j)
Considered clinically unstable for any condition
k) Serious comorbid non cardiovascular disease in which the life expectancy of the subject 
is < 3 months
l)
Liver disease defined as history of cirrhosis with evidence of portal hypertension such as 
varices, or encephalopathy, or total bilirubin > 3 mg/dL (> 51 μmol/L) or significant 
elevation of liver enzymes (AST, ALT > 3 times the upper limit of normal)
m) Prior solid organ transplant
3) Prior/Concomitant Therapy
a) Treatment with oral phosphodiesterase type 5 (PDE5) inhibitor sildenafil, vardenafil or 
avanafil within 24 hours of study drug infusion or treated with tadalafil within 4 days of 
study drug infusion 
b) Treatment with intravenous inotropic therapy (dobutamine, milrinone, levosimendan) in 
the previous month or planned treatment in next 3 months.
c) Current treatment with chronic oral, transdermal or sublingual nitrates, except at the 
discretion of the investigator and treating physician, nitrates could be temporarily 
interrupted. In which case, an interruption of 3 days is required prior to start of study 
drug.
4) Physical and Laboratory Test Findings
a) Estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m2
b) Have persistent abnormal serum electrolytes not resolved between screening and start of 
the study drug infusion, as defined by any of the following:
i)
A sodium (Na+) concentration < 130 or > 145 mEq/L (mmol/L)
ii) A potassium (K+) concentration < 3.2 or > 5.5 mEq/L (mmol/L)
c) Have severe anemia, as documented by a hemoglobin < 9 g/dL (< 5.59 mmol/L)
5) Allergies and Adverse Drug Reaction
a) Any history of allergic reaction to BMS-986231, or its components, Captisol® or 
potassium acetate. 
Revised Protocol No.: 05
Date: 24-Jan-2019
35
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
b)
Allergic reactions to organic nitrates
6) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to 
continue as a participant. Strict conditions apply and Bristol-Myers Squibb’s approval is 
required.
b) Participants who are compulsorily detained for treatment of either a psychiatric or 
physical (e.g., infectious disease) illness
c) Participation in an investigational clinical drug study within 30 days or 5 elimination 
half-lives, (whichever is longer) prior to randomization.
d) Prior participation and treatment in a study using BMS-986231, CXL-1427, or 
CXL-1020
e) Alcohol beverage consumption within 6 hours prior to randomization. 
f)
Low quality echocardiographic visualization windows and image acquisition
g) Body weight < 45 kg or ≥140 kg
h) Known hypersensitivity or contra-indication to the intravenous echocardiography contrast 
agent, in the event contrast echocardiography is used
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3
Lifestyle Restrictions
Participants are not permitted to consume alcohol-containing beverages from midnight of the day 
before the treatment day until the day after the treatment day (Day 1 of each period).
6.4
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomized. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participants, to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries from 
regulatory authorities. Minimal information includes date of consent, demography, screen failure 
details, eligibility criteria, and any serious AEs.
6.4.1
Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment of a participant that has 
discontinued the study as a pre-randomization failure (i.e., participant has not been randomized). 
If re-enrolled, the participant must be re-consented.
Laboratory parameters and/or assessments that are included in Table 2.-1, Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participants. Consultation 
Revised Protocol No.: 05
Date: 24-Jan-2019
36
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
with the Medical Monitor may be needed to identify whether repeat testing of any particular 
parameter could allow for the patient to be randomized.
7
TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
randomization or treatment allocation
Study treatment includes both Investigational [Medicinal] Product (IP/IMP) and Non-
investigational [Medicinal] Product (Non-IP/Non-IMP). 
An investigational product, also known as investigational medicinal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study, including products already with a marketing authorization but used 
or assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
In this study the investigational products are BMS-986231 for injection, nitroglycerin, and 
placebo.
Other medications used as support or escape medication for preventative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be 
considered as non-investigational products. 
In this study, the required Potassium Acetate used as a buffer for BMS-986231 infusions is 
considered non-investigational product.
Study medication will be prepared by an unblinded pharmacist (or appropriate designee) in the 
Day 1 of each period (treatment day), at time of randomization in the first period and before start 
of the infusion for the subsequent 2 periods. Detailed instructions for preparing, reconstituting, 
and handling of BMS-986231 and placebo, as well as infusion setups, instructions for labeling 
individual infusion bags after they are prepared, and information on dosing solution stability are 
provided in the Study Pharmacy Manual.
Table 7.-1:
Study treatments for CV013020
Product 
Description / 
Class and 
Dosage Form
Potency
IP/Non-IMP
Blinded or 
Open Label
Packaging / 
Appearance
Storage 
Conditions
(per label)
BMS-986231For 
Injectiona
240 mg/vial  
IP
Open Label
Vial(s) in a 
carton
Refer to the label 
on container 
and/or pharmacy 
manual
Potassium 
Acetate Injection, 
USPb
2 mEq/mL
Non-IMP
Open Label
Vial(s) in a 
carton.
Refer to the label 
on container or 
package insert / 
summary of 
product 
Revised Protocol No.: 05
Date: 24-Jan-2019
37
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Table 7.-1:
Study treatments for CV013020
Product 
Description / 
Class and 
Dosage Form
Potency
IP/Non-IMP
Blinded or 
Open Label
Packaging / 
Appearance
Storage 
Conditions
(per label)
characteristics
Nitroglycerin 
injectionc
5 mg/mL
(50 mg/10 mL 
Single Dose 
Vial or
Ampoule)
IP
Open Label
Vial(s) or
Ampoule(s) in a 
carton
Refer to the label 
on container or 
package insert / 
summary of 
product 
characteristics
a BMS-986231 for infusion contains active pharmaceutical ingredient BMS-986231 240 mg/vial formulated with 
Captisol® 3405 mg/vial 
b Potassium Acetate Injection may be supplied by BMS centrally (ex-US sites) or through site sourcing procedures. 
It is used as a buffer for BMS-986231 infusion (1 mEq potassium per 100 mL of reconstituted BMS-986231 further 
diluted for infusion).
c Nitroglycerin may be supplied by BMS centrally or through site sourcing procedures.
Revised Protocol No.: 05
Date: 24-Jan-2019
38
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
7.1
Treatments Administered
The selection and timing of dose for each participant is as follows:
Table 7.1-1:
Selection and Timing of Dose
Study Treatment
Unit dose strength(s)/Dosage level(s)
Dosage formulation
Frequency of 
Administration
Route of 
Administration
BMS-986231 
3 μg/kg/min for 10 min (5 mL/H)
6 μg/kg/min for 10 min (10 mL/H)
12 μg/kg/min for the rest of the 5-hour 
infusion (20 mL/H)
Single infusion
IV
Nitroglycerin 
20 μg/min for 10 min (5 mL/H)
40 μg/min for 10 min (10 mL/H)
80 μg/min for the rest of the 5-hour infusion 
(20 mL/H)
Single infusion
IV
Placebo*
5 mL/H for 10 min
10 mL/H) for 10 min
20 mL/H for the rest of the 5-hour infusion
Single infusion
IV
* Placebo will be a solution of 5% dextrose (D5W) that will be locally supplied by the sites.
7.2
Method of Treatment Assignment
Study using Interactive Response Technology (IRT): All participants will be centrally 
randomized using an Interactive Response Technology (IRT). Before the study is initiated, each 
user will receive login information and directions on how to access the IRT.
Study treatment will be dispensed at the study visits as listed in Schedule of Activities (Section 
2).
Enrolled participants, including those not dosed, will be assigned sequential participant numbers 
starting with 00001, (e.g., 00001, 00002, 00003.... 00010). Those enrolled participants meeting 
inclusion and exclusion criteria will be eligible to be randomized. Randomization numbers will 
be assigned prior to dosing. Subjects who are re-enrolled (See Section 6.4) will be assigned a 
new participant number.
Participants will not be replaced if they are discontinued from the study.
7.3
Blinding
7.3.1
Emergency Unblinding
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual participant in which knowledge of 
the investigational product is critical to the participant's management, the blind for that 
participant may be broken by the investigator. The participant’s safety takes priority over any 
other considerations in determining if a treatment assignment should be unblinded.
Revised Protocol No.: 05
Date: 24-Jan-2019
39
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Before breaking the blind of an individual participant's treatment, the investigator should 
determine that the unblinded information is necessary, i.e., that it will alter the participant's 
immediate management. In many cases, particularly when the emergency is clearly not related to 
the investigational product, the problem may be properly managed by assuming that the 
participant is receiving active product. It is highly desirable that the decision to unblind treatment 
assignment be discussed with the Medical Monitor, but the investigator always has ultimate 
authority for the decision to unblind. The Principal Investigator should only call in for
emergency unblinding AFTER the decision to discontinue the participant has been made.
For this study, the method of unblinding for emergency purposes is via the Interactive Response 
Technology (IRT) system. For information on how to unblind in an emergency, consult the IRT 
manual.
In cases of accidental unblinding, contact the Medical Monitor and ensure every attempt is made 
to preserve the blind.
Any request to unblind a participant for non-emergency purposes should be discussed with the 
Medical Monitor.
7.3.2
Other Blinding and Unblinding
The Bioanalytical Sciences section or its designate may be unblinded to the randomized 
treatment assignments, in order to minimize unnecessary assays of samples from subject during 
the placebo treatment period.  Likewise, the Biotransformation section or its designate may be 
unblinded, if metabolite profiling work is conducted.
In certain circumstances, a pharmacokineticist or designate(s) in Clinical Pharmacology and 
Pharmacometrics, biostatistician(s) and programmer(s) at BMS, or designee, may be unblinded 
in order to prepare preliminary summaries of PK and safety data, as needed.  These summaries 
will not reveal individual subjects’ treatment sequence assignments.
7.4
Dosage Modification
The administration of the study drugs will be done through an infusion pump connected to a 
single peripheral IV line. After priming the infusion set tubing and connecting the lines to the 
intravenous catheter, the pump should be set to deliver the rates of infusion indicated on the 
infusion bag label according to the up-titration schedule (See Section 5.1
The pump infusion volume display should be re-set to 0 after priming the infusion line and just 
prior to the start of the infusion, and the total volume infused at the conclusion of the infusion 
after 5hours, or at the time of any early discontinuation, should be recorded in the clinic source 
documents.
At any time during the administration of study drug, the study drug infusion must be 
discontinued if an adverse event or any other safety issue suggests it is not in the patient’s best 
interest to continue to receive study drug.
Revised Protocol No.: 05
Date: 24-Jan-2019
40
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
The investigator has the option to adjust the study drug dosage level downward by 50%
interrupt or discontinue the study drug infusion in patients that develop hypotension, or if the 
patient experiences symptomatic hypotension that is not easily tolerated, as follows (and shown 
in Figure 7.4-1
•
Study drug reduction: Study drug is decreased by 50% if SBP decreases to levels <90 
mmHg but ≥80 mmHg. The dose cannot be subsequently increased.
•
Study drug interruption: Study drug is interrupted for 1 hour if SBP decreases to <80 
mmHg or symptoms of low blood pressure occur within the first 4 hours of infusion. If the 
SBP is ≥105 mmHg after one hour interruption, the study drug could be resumed at 50 % of 
the dose to complete 5-hours of effective study drug infusion.
•
Study drug discontinuation: Study drug will be permanently discontinued if SBP remains 
< 105 mmHg after 1 hour interruption or if SBP decreases to levels <80 mmHg or symptoms 
of low blood pressure occur after 4 hours of infusion. 
End of infusion procedures should be done as soon as possible after interruption or 
discontinuation of the study drug.  If an infusion in a given period is discontinued, patients 
remain eligible to complete subsequent periods.  
Figure 7.4-1
BP Management Algorithm
Any decision to lower the dosage level of study drug or discontinue study drug should be based 
on the investigator’s assessment of the patient’s overall clinical stability, in the context of 
appropriate ongoing monitoring of the patient’s condition.
Revised Protocol No.: 05
Date: 24-Jan-2019
41
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
A 50% dosage adjustment downward will be achieved by decreasing the rate of study drug 
infusion from 20 mL/H to 10 mL/H.
In order to ensure compatibility with BMS-986231 and NTG, the placebo solution will be D5W.
7.5
Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study Participants. The investigational product must be dispensed only from official study sites 
by authorized personnel according to local regulations.
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment 
should not be dispensed and contact BMS immediately.
Study treatment not supplied by BMS will be stored in accordance with the package insert.
Please refer to Pharmacy Manual for additional guidance on storage of study drug. Study drug 
not supplied by BMS will be stored in accordance with the package insert. Please refer to 
Appendix 2 for guidance on IP records and documentation.
Once study medication is reconstituted by the unblinded pharmacist, it will remain stable at room 
temperature for a maximum of 8 hours. Reconstituted study medication must be refrigerated 
immediately if dosing will not start within 1 hour.
It is recommended that study medication be removed from the refrigerator and left at room 
temperature for approximately 30 minutes prior to the start of the infusion
Investigational product documentation (whether supplied by BMS or not) must be maintained 
that includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration, storage temperatures, reconstitution, and use of 
required processes (e.g., required diluents, administration sets).
Further guidance and information for final disposition of unused study treatment are provided in 
Appendix 2.  
7.5.1
Retained Samples for Bioavailability / Bioequivalence
Not Applicable.
7.6
Treatment Compliance
Not applicable.
7.7
Concomitant Therapy
7.7.1
Prohibited and/or Restricted Treatments
•
Initiation of PDE5 inhibitors is prohibited during study drug infusion and 24 hours after the 
end of the study drug.
Revised Protocol No.: 05
Date: 24-Jan-2019
42
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Administration of IV vasoactive drugs (such as dopamine, dobutamine, enoximone, 
nitroprusside, levosimendan or milrinone) is not permitted during study drug infusion 
•
Chronic oral heart failure medications (diuretics, ACE inhibitors, ARBs, MRA, beta-
blockers, calcium antagonists)  will be withheld in the morning of the treatment day and will 
be administered after the end of the study drug infusion
•
Initiation of chronic oral, transdermal or sublingual nitrates is prohibited during the treatment 
period.
7.7.2
Other Restrictions and Precautions
Not applicable
7.7.2.1
Imaging Restriction and Precautions
Not applicable.
7.8
Treatment After the End of the Study
At the end of the study, BMS will not continue to provide BMS supplied study treatment to 
participants/investigators unless BMS chooses to extend the study. The investigator should 
ensure that the participant receives appropriate standard of care to treat the condition under 
study.
8
DISCONTINUATION CRITERIA
8.1
Discontinuation from Study Treatment
Participants MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:
•
Participant’s request to stop study treatment. Participants who request to discontinue study 
treatment will remain in the study and must continue to be followed for protocol specified 
follow-up procedures. The only exception to this is when a participant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by the 
participant to provide this information
•
Any clinical adverse event (AE), laboratory abnormality or inter-current illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the 
best interest of the participant
•
Termination of the study by Bristol-Myers Squibb (BMS)
•
Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatment of either a psychiatric or physical (e.g., infectious disease) illness
•
If study medication has been interrupted for low blood pressure, resumed, and an episode of 
hypotension (or symptoms of hypotension) reoccurs
Refer to Section 2 the Schedule of Activities for data to be collected at the time of treatment 
discontinuation and follow-up, and for any further evaluations that can be completed
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In the event a normal healthy female participant becomes 
Revised Protocol No.: 05
Date: 24-Jan-2019
43
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
pregnant during a clinical trial, the study treatment must be discontinued immediately. In most 
cases, the study treatment will be permanently discontinued in an appropriate manner (e.g., dose 
tapering if necessary for participant safety). Please call the BMS Medical Monitor within 
24 hours of awareness of the pregnancy. If the investigator determines a possible favorable 
benefit/risk ratio that warrants continuation of study treatment, a discussion among the 
investigator, the BMS Medical Monitor/designee and the patient must occur.
All participants who discontinue study treatment should comply with protocol specified follow-
up procedures as outlined in Section 9. The only exception to this requirement is when a 
participant withdraws consent for all study procedures including post-treatment study follow-up 
or loses the ability to consent freely (i.e., is imprisoned or involuntarily incarcerated for the 
treatment of either a psychiatric or physical illness).
If study treatment is discontinued prior to the participant’s completion of the study, the reason 
for the discontinuation must be documented in the participant’s medical records and entered on 
the appropriate case report form (CRF) page.
8.1.1
Post Study Treatment Study Follow-up
In this study, follow-up is a key endpoint of the study. Post study follow-up is of critical 
importance and is essential to preserving participant safety and the integrity of the study. 
Participants who discontinue study treatment must continue to be followed for collection of 
outcome and/or survival follow-up data as required and in line with Section 9 until death or the 
conclusion of the study.
Participants who discontinue study treatment may continue to be followed.
8.2
Discontinuation from the Study
Participants who request to discontinue study treatment will remain in the study and must 
continue to be followed for protocol specified follow-up procedures. The only exception to this 
is when a participant specifically withdraws consent for any further contact with him/her or 
persons previously authorized by the participant to provide this information. 
•
Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
•
The withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study treatment only 
or also from study procedures and/or post treatment study follow-up, and entered on the 
appropriate CRF page.
•
In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.
•
If the participant withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
Revised Protocol No.: 05
Date: 24-Jan-2019
44
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
8.3
Lost to Follow-Up
•
All reasonable efforts must be made to locate participants to determine and report their 
ongoing status. This includes follow-up with persons authorized by the participant.
•
Lost to follow-up is defined by the inability to reach the participant after a minimum of three
documented phone calls, faxes, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in the participant’s medical 
records.
•
If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
•
If investigator’s use of third-party representative to assist in the follow-up portion of the 
study has been included in the participant’s informed consent, then the investigator may use a 
Sponsor retained third-party representative to assist site staff with obtaining participant’s 
contact information or other public vital status data necessary to complete the follow-up 
portion of the study. 
•
The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information.
•
If after all attempts, the participant remains lost to follow-up, then the last known alive date 
as determined by the investigator should be reported and documented in the participant’s 
medical records.
9
STUDY ASSESSMENTS AND PROCEDURES
•
Study procedures and timing are summarized in Section 2 the Schedule of Activities. 
•
Protocol waivers or exemptions are not allowed.
•
All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
•
Adherence to the study design requirements, including those specified in the Section 2
Schedule of Activities, is essential and required for study conduct.
•
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria before randomization. The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.
•
Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count) and obtained before signing of informed consent may be utilized for screening or 
baseline purposes provided the procedure meets the protocol-defined criteria and has been 
performed within the timeframe defined in Section 2 the Schedule of Activities.
Revised Protocol No.: 05
Date: 24-Jan-2019
45
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
9.1
Efficacy Assessments
9.1.1
Imaging Assessment for the Study
Echocardiography
A central core lab will perform all echocardiographic analyses in this study. Sites should be 
trained prior to scanning the first study participant. Image acquisition guidelines and submission 
process will be outlined in the Imaging Manual to be provided by the core lab.
Prior to enrollment in the study, study participants will undergo a screening echocardiography 
that will be submitted to the core lab for review to confirm eligibility. It will assess the ejection 
fraction and the quality of echocardiography images and windows. 
Contrast echocardiograms could be considered in selected patients to enhance image quality in 
those patients with poor endocardial definition. Contrast echocardiography should only be used 
if the sonographer and the investigative site meet the following conditions: are skilled in the 
administration of contrast agents and routinely use the technique in their clinical practice, are 
fully aware of the indications and contraindications for the use of contrast, are trained in the 
immediate recognition and management of adverse events, and have the necessary equipment, 
drugs, and supplies readily available for managing adverse events.  For further details, please 
refer to the echo lab manual.
At least 2 echocardiograms will be performed on the first day of each period (prior to infusion 
and at the end of the infusion between hour 4 and hour 5 of the infusion). If the study drug is 
prematurely interrupted, a supplementary echocardiogram will be performed as soon as possible 
after interruption. If the study drug is resumed, another echocardiogram will be performed 
between hour 4 and hour 5 of the effective perfusion time.
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment.
Whole body bioimpedance
NICaS device will non-invasively assess cardiac output based on whole body bioimpedance; it 
has been demonstrated to meet FDA standards for bioequivalence when compared to 
thermodilution-based cardiac output methods34. 
Pulse wave analysis
Noninvasive central aortic pressure measurement and waveform analysis will be performed in 
this study at time-points indicated in Table 2.-2 (time and events schedule). Mean cardiac power 
will be calculated as the product of measured cardiac output (or index) and mean central aortic 
blood pressure35.
9.2
Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3.
Revised Protocol No.: 05
Date: 24-Jan-2019
46
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative). 
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or the study, or that caused the 
participant to discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 3
9.2.1
Time Period and Frequency for Collecting AE and SAE Information
The collection of non-serious AE information begins at initiation of study treatment until 
24 hours after discontinuation of the infusion at the time-points specified in Section 2 the 
Schedule of Activities (Section 2). Non-serious AE information should also be collected from the 
start of a placebo lead-in period or other observational period intended to establish a baseline 
status for the participants.
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB)33 represent the Reference Safety 
Information to determine expectedness of serious adverse events for expedited reporting. 
Following the participant’s written consent to participate in the study, all SAEs, whether related 
or not related to study drug, must be collected, including those thought to be associated with 
protocol-specified procedures.
All SAEs must be collected that occur during the screening period and within 30 days of 
discontinuation of dosing.
The investigator must report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure.
•
Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded on the appropriate section of the eCRF section.
•
All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3. 
•
The investigator will submit any updated SAE data to the sponsor within 24 hours of this 
being available.
Investigators are not obligated to actively seek AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a death, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the 
study treatment or study participation, the investigator must promptly notify the sponsor.
The method of evaluating, and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
Revised Protocol No.: 05
Date: 24-Jan-2019
47
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
9.2.2
Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a participant. (In order to prevent reporting bias, participants 
should not be questioned regarding the specific occurrence of one or more AEs.)
9.2.3
Follow-up of AEs and SAEs
•
Non-serious AEs should be followed to resolution or stabilization, or reported as SAEs if 
they become serious (see Section Appendix 3).
•
Follow-up is also required for non-serious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate.
•
 All identified non-serious AEs must be recorded and described on the non-serious AE page 
of the CRF (paper or electronic). Completion of supplemental CRFs may be requested for 
AEs and/or laboratory abnormalities that are reported/identified during the course of the 
study.
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest (as defined in 
Section 9.2 will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the participant is lost to follow-up (as defined in Section 8.3).
Further information on follow-up procedures is given in Appendix 3.
9.2.4
Regulatory Reporting Requirements for SAEs
•
Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.
•
An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor will file it along with 
the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
Sponsor or designee will be reporting adverse events to regulatory authorities and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and 
FDA Code of Federal Regulations 21 CFR Parts 312 and 320. A SUSAR (Suspected, 
Unexpected Serious Adverse Reaction) is a subset of SAEs and will be reported to the 
appropriate regulatory authorities and investigators following local and global guidelines and 
requirements.
9.2.5
Pregnancy
If, following initiation of the study treatment, it is subsequently discovered that a participant is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5 half-lives after product administration, the investigator must immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance 
Revised Protocol No.: 05
Date: 24-Jan-2019
48
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Form to BMS Designee within 24 hours of awareness of the event and in accordance with SAE 
reporting procedures described in Appendix 3
In most cases, the study treatment will be permanently discontinued in an appropriate manner 
(e.g., dose tapering if necessary for participant safety). Please call the BMS Medical Monitor 
within 24 hours of awareness of the pregnancy.
Protocol-required procedures for study discontinuation and follow-up must be performed on the 
participant.
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collect any pregnancy surveillance 
information from the female partner, the female partner must sign an informed consent form for 
disclosure of this information. Information on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
9.2.6
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the non-serious AE 
CRF page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a 
back-up option when the electronic system is not functioning.
•
Any laboratory test result that is clinically significant or meets the definition of an SAE 
•
Any laboratory test result abnormality that required the participant to have study treatment 
discontinued or interrupted
•
Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by 
the reporting investigator (e.g., anemia versus low hemoglobin value).
9.2.7
Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs (see Section 9.2 and Appendix 3 for 
reporting details).
Potential drug induced liver injury is defined as: 
1) AT (ALT or AST) elevation > 3 times upper limit of normal (ULN) if baseline values are 
within the normal range, or > 2 times the baseline values in case of baseline values above the 
upper limit of normal (ULN)
AND
Revised Protocol No.: 05
Date: 24-Jan-2019
49
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND
3) No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, worsening heart failure, viral hepatitis, pre-existing chronic or 
acute liver disease, or the administration of other drug(s) herbal medications or substances 
known to be hepatotoxic.
9.2.8
Other Safety Considerations
Any 
significant 
worsening 
noted 
during 
interim 
or 
final 
physical 
examinations, 
electrocardiogram, x-ray filming, any other potential safety assessment required or not required 
by protocol should also be recorded as a non-serious or serious AE, as appropriate, and reported 
accordingly.
9.3
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be 
reported as an SAE (see Section 9.2).
Since there is limited clinical experience with BMS-986231, there is no current knowledge with 
overdosing, hence no specific guidance is currently available. In case of acute overdose, it is not 
known if dialysis would accelerate drug clearance. BMS-986231 produces vasodilation as a 
component of its hemodynamic effects. Thus, the most immediate adverse effect in the case of 
overdose of BMS-986231 may be hypotension, mediated at least in part by mechanisms similar 
to the hypotensive activity of intravenous nitroglycerin through activation of soluble guanylate. 
No specific pharmacologic antidote to HNO effects exists. In previous studies with BMS-986231 
in healthy volunteers and advanced heart failure subjects, cessation of drug was adequate to 
restore blood pressure within 1-2 hours. In the event of an overdose, the infusion should be 
discontinued, and other therapies administered concurrently that have vasodilatory effects should 
be discontinued. Volume repletion, either orally or intravenously, can be used to counter the 
clinical effects of HNO mediated vasodilation, but should be used with extreme caution in 
decompensated heart failure subjects. If marked hypotension occurs, appropriate treatment, 
including intravenous pressor agents may be required to support blood pressure.
9.4
Safety
Planned time points for all safety assessments are listed in Section 2 the Schedule of Activities.
9.4.1
Physical Examinations
Refer to Section 2: Schedule of Activities.
9.4.2
Vital signs
Refer to Section 2: Schedule of Activities.
Revised Protocol No.: 05
Date: 24-Jan-2019
50
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
9.4.3
Electrocardiograms
Refer to Section 2: Schedule of Activities.
9.4.4
Clinical Safety Laboratory Assessments
Investigators 
must 
document 
their 
review 
of 
each 
laboratory 
safety 
report.
Subjects will have laboratory tests performed locally and centrally as described in the following 
sections. A central/local laboratory will perform the analyses and will provide reference ranges 
for these tests.
Local laboratory assessments
The following local laboratory tests will be performed as part of the screening evaluation and in 
the morning of each treatment day. Results will be recorded in the study eCRF. 
Hematology
•
Hemoglobin
•
Hematocrit
•
White blood cell count and differential
•
Platelet count
Serum chemistry
•
Aspartate Aminotransferase (AST, SGOT)
•
Alanine Aminotransferase (ALT, SGPT)
•
Total Bilirubin
•
Blood Urea Nitrogen (BUN)
•
Electrolytes
o
Sodium
o
Potassium
•
Serum Creatinine (Scr)
•
eGFR by equation used locally 
Other Analyses
BNP or NT-pro BNP (according to local lab availability) will be performed at screening
Pregnancy test (WOCBP only: screening, pre-dose in each treatment period,).
Follicle stimulating hormone (FSH) (screening only for women only) 
In each treatment day, the study drug infusion could start without waiting for the results of the 
laboratory assessments done in the morning of the treatment day at the study facility if the 
following criteria are met:
•
The results of the laboratory assessment at screening / previous period are within ranges 
compatible with inclusion/exclusion criteria.
Revised Protocol No.: 05
Date: 24-Jan-2019
51
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
The study participant had a stable condition and didn’t have any change in medication since 
the screening visit / previous period. 
Central laboratory assessments
The following laboratory tests will be performed and submitted to the Central Laboratory for 
analysis as per the Study Assessment and Procedures
Hematology
•
Hemoglobin
•
Hematocrit
•
White blood cell count, including differential
•
Platelet count
Serum Chemistry
•
Aspartate Aminotransferase (AST, SGOT)
•
Alanine Aminotransferase (ALT, SGPT)
•
Total bilirubin
•
Direct bilirubin
•
Alkaline phosphatase
•
Lactate dehydrogenase (LDH)
•
Serum Creatinine (Scr)
•
Blood Urea Nitrogen (BUN)
•
Uric acid 
•
Fasting glucose
•
Total Protein
•
Albumin
•
Electrolytes
o
Sodium
o
Potassium
o
Chloride
o
Calcium
o
Phosphorus
o
Magnesium
•
Creatine kinase (Creatine Phosphokinase) (CK) (CPK)
•
Biomarkers: cystatin C, N-Gal
Urinalysis
•
Protein
•
Glucose
•
Blood
•
Leukocyte esterase
Revised Protocol No.: 05
Date: 24-Jan-2019
52
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Specific gravity
•
pH
•
Microscopic examination of the sediment if blood, protein or leukocytes esterase are positive 
on the dipstick
The detailed methods for specimen collection, handling, processing, shipping, and storage will 
be supplied in the Investigator’s Laboratory Manual provided by the Central Laboratory.
9.4.5
Suicidal Risk Monitoring
Not applicable
9.4.6
Imaging Safety Assessment
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment. 
9.5
Pharmacokinetic Assessments
Blood samples will be collected for pharmacokinetic assessments as described in Table 9.5-1. 
Table 9.5-1:
Pharmacokinetic Assessments
Study Day of Sample 
Collection
Event
Time
(Relative To Dose) 
Hour: Min
Blood Sample
1
Pre-dose
00:00
x
1
0.5 hour
(± 15min)
00:30
x
1
1 hour
(± 30min)
01:00
x
1
4.5 hours* (± 30min)
04:30
x
1
7 hours
(± 30min)
07:00
x
1
Dose lowered due to 
safety event (± 30min)
Misc.
x
1
Early Discontinuation
Misc.
x
*end of the infusion sample should be taken as close to the end of the infusion as possible 
In addition, collect a PK sample from the patient when the dose is lowered due to a safety event 
and also at time of early discontinuation of study drug. The sample should be collected 
immediately before or after the decision to change the dose was made.
Revised Protocol No.: 05
Date: 24-Jan-2019
53
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Blood samples will be collected from all subjects at pre-dose, 0.5, 1 and 4.5 hours during 
infusion and 2 hours after end of infusion and plasma concentrations will be measured using 
LC-MS.
9.6
Pharmacodynamics
Not applicable.
9.7
Pharmacogenomics
9.7.1
ADME Sampling
A 6-mL whole blood sample will be drawn at baseline (Day 1, as indicated in Section 2 Schedule 
of Activities) for potential analysis of DNA variants in genes solely related to disposition of 
BMS-986231 (Drug absorption, distribution, metabolism, and excretion (ADME) related genes 
such as mARC, CYP, uridine 5’-diphospho-glucuronosyltransferase (UGT), reducing and 
hydrolytic enzymes and drug transporters), except where prohibited by local laws or regulations. 
Investigation of polymorphisms in ADME genes will only be conducted in the event that 
variable PK is observed. Further details of blood collection and processing will be provided to 
the site in the procedure manual.
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 05
Date: 24-Jan-2019
54
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
 
 
 
 
 
 
 
 
 
 
 
9.9
Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Economics parameters will not be 
evaluated in this study.
10
STATISTICAL CONSIDERATIONS
10.1
Sample Size Determination 
Based on a review of stroke volumes and stroke volume indices from the literature36,37, baseline
stroke volume index generally ranged from 30-40 mL/m², with inter-individual SD of 
approximately 25 – 35% of the mean. Likewise, SV values generally ranged from 50-70 mL, 
with inter-individual SD of approximately 25 – 35% of the mean. Results from these studies 
also suggest intra-individual correlations in the range of 0.6 – 0.8.  
Revised Protocol No.: 05
Date: 24-Jan-2019
55
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Sample size calculations assume baseline SVI of approximately 30 mL/m², with placebo values 
consistent with baseline, an increase of 15% from baseline, relative to placebo, as meaningful 
(e.g. 4.5 mL/m²), an inter-individual SD of 10 mL/m², and intra-individual correlations for the 
difference between placebo and HNO of 0.7. Using these assumptions, approximately 36 
subjects with data from treatment periods being compared will be required to achieve a power of 
90%, with a type I error probability of 0.05 (2-sided). In order to address the potential for 
missing data arising from dropout, an allowance of 15% subjects will be included, with a 
resulting target sample size of 42 subjects to be randomized. Sample sizes are calculated based 
on method IV from Mehrotra38, which compares post baseline values, adjusting for the 
differences in the baseline value.
10.2
Populations for Analyses
For purposes of analysis, the following populations are defined:
Population
Description
Enrolled 
All participants who sign informed consent
Randomized
All randomized subjects who have started study drug infusion in 
at least one treatment period. This is also known as the Intent to 
Treat (ITT) population. Data in this data set will be analyzed 
based on randomized sequence of treatments.
Safety
All randomized participants who take at least 1 dose of double-
blind study treatment. Participants will be included in the 
treatment group they received in each period.
10.3
Statistical Analyses
The statistical analysis plan will be developed and finalized before database lock and will 
describe the selection of participants to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data. Below is a summary of planned statistical 
analyses of the primary and secondary endpoints.  For analyses involving baseline, the baseline 
value is defined by the last value prior to the start of infusion for a specified period, unless 
otherwise noted.
Revised Protocol No.: 05
Date: 24-Jan-2019
56
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
10.3.1
Efficacy Analyses
Endpoint
Statistical Analysis Methods
Primary
Stroke volume index derived from the left ventricular outflow tract (LVOT) 
Doppler echocardiogram will be assessed using a contrast comparing placebo 
and BMS-986231 from a mixed model repeated measures (MMRM) analysis, 
with sequence, treatment period, and treatment, and the difference in the 
treatment 
period 
baselines 
as 
a 
covariate39. 
The 
Kenward-Roger 
approximation for the degrees of freedom will be specified for the model. 
Estimation of the variance covariance will be based on unstructured (UN) R 
matrix assuming no common variances or covariances.
Secondary
Analyses of secondary endpoints will use a similar model as for the primary 
endpoints.
For comparisons with NTG, the contrast and covariates will refer to values 
from the treatment periods using NTG and BMS-986231.  
No adjustments will be made for multiple comparisons.
10.3.2
Safety Analyses
All safety analyses will be performed on the Safety Population (see Section 10.2).
For safety analyses, all recorded adverse events for each period will be listed and tabulated by 
system organ class, preferred term and treatment. Vital signs and clinical laboratory test results 
will be listed and summarized by treatment. Any significant physical examination findings, and 
clinical laboratory results will be listed. ECG readings will be evaluated by the investigator and 
abnormalities, if present, will be listed.
10.3.3
Other Analyses
Results for other endpoints will be summarized descriptively.  Model-based analyses may be 
performed, using models similar to the model for the primary endpoint. DNA variants in genes 
related to mARC and in ADME related genes will be performed if extensive between-subject 
variability in exposure of BMS-986231 is observed. Results may be reported in a separate report.
10.3.4
Pharmacokinetic Analyses
Pharmacokinetic parameters for BMS-986231 and BMT-284730 and other metabolites 
(eg, BMT-279554 & CAR-000463) will be estimated as appropriate. The plasma concentration 
may also be used to conduct population pharmacokinetic analysis and exposure-response 
analysis with select efficacy and safety endpoints. Results of the population pharmacokinetic and 
exposure-response analysis will be reported in a separate report.
10.3.5
Interim Analyses 
Not applicable.
Revised Protocol No.: 05
Date: 24-Jan-2019
57
6.0
Approved
930114837
6.0
v










Clinical Protocol
CV013020
BMS-986231
HNO Donor
12
APPENDICES
Revised Protocol No.: 05
Date: 24-Jan-2019
62
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
APPENDIX 1
ABBREVIATIONS AND TRADEMARKS
Term
Definition
A-wave
A-wave late active filling of LV
ACC
American College of Cardiology
ACEi
angiotensin-converting-enzyme inhibitor
ADHF
acute decompensated heart failure
ADME
absorption, distribution, metabolism, and excretion
AE
adverse event
AHA
American Heart Association
ALT
alanine aminotransferase
AR
additional research
ARB
angiotensin receptor blockers 
ARNI
angiotensin-receptor/neprilysin inhibitor 
AST
aspartate aminotransferase
BiV
biventricular
BMS
Bristol-Myers Squibb
BNP
brain natriuretic peptide
BPM
beats per minute
BUN
blood urea nitrogen
CHF
congestive heart failure
CI
cardiac index
CRF
case report form
CRP
C-reactive protein
CVA
cerebrovascular accident
D5W
5% dextrose in water
DBP
diastolic blood pressure
DDD
pacemaker dual chamber pacing and sensing, both triggered and inhibited 
mode 
DILI
drug induced liver injury
DNA
deoxyribonucleic acid
DT
deceleration time
DTI
doppler tissue imaging
ECG
electrocardiogram
EDPVR
end-diastolic pressure volume relationship
EDT
E-wave deceleration time
eGFR
estimated glomerular filtration rate
ER
exposure-response
ESC
European Society of Cardiology 
ESPVR
end systolic pressure-volume relationship
E-wave
E-wave early passive filling of the left ventricle
FDA
Food and Drug Administration
Revised Protocol No.: 05
Date: 24-Jan-2019
63
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Term
Definition
FSH
follicle stimulating hormone
GLS
global longitudinal strain
HF
heart failure
HFrEF
heart failure with reduced ejection fraction
HNO
Nitroxyl, Nitrosyl Hydride, or hydrogen Oxonitrate
HR
heart rate
IB
investigator brochure
IEC
independent ethics committee
IP
investigational product
IRB
institutional review board
IRT
interactive response technology
ITT
intent to treat
IV
intravenous
IVRT
isovolumetric relaxation time
K+
Potassium
LA
left atrium
LC-MS
liquid chromatography–mass spectrometry
LDH
lactate dehydrogenase
LV
left ventricle
LVEF
left ventricular ejection fraction
LVOT
left ventricular outflow tract
MAP
mean arterial pressure
mARC
mitochondrial amidoxime-reducing component
MI
myocardial infarction
MMRM
mixed model repeated measures
MRA
mineralocorticoid receptor antagonists
Na+
Sodium
NCV
nerve conduction velocities
NICaS
non invasive cardiac system
NO
nitric oxide
NTG
nitroglycerin
NT-pro BNP
N terminal- pro BNP
NYHA
New York Heart Association
PADP
pulmonary artery diastolic pressure
PCWP
pulmonary capillary wedge pressure
PDE5
phosphodiesterase type 5
pH
potential of hydrogen
PK
pharmacokinetic
PRSW
preload recruitable stroke work
RA
right atrium
Revised Protocol No.: 05
Date: 24-Jan-2019
64
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Term
Definition
RAP
right atrial pressure
RNA
ribonucleic acid
RTR2
ryanodine receptor 2
RV
right ventricle
SAE
serious adverse event
SBP
systolic blood pressure
Scr
serum creatinine
SD
standard deviation
sGC
soluble guanylate cyclase
SGOT
serum glutamic-oxaloacetic transaminase
SGPT
serum glutamic pyruvic transaminase
STE
speckle-tracking echocardiography
SUSAR
suspected, unexpected serious adverse reaction
SVI
stroke volume index
TAPSE
tricuspid annular plane systolic excursion
TIA
transient ischemic attack
TR
tricuspid regurgitation
ULN
upper limit of normal
VTI
velocity time integral
VVI
pacemaker single chamber, ventricular pacing in the inhibited mode
WOCBP
women of child bearing potential
Revised Protocol No.: 05
Date: 24-Jan-2019
65
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
APPENDIX 2
STUDY GOVERNANCE CONSIDERATIONS
The term ‘Participant’ is used in the protocol to refer to a person who has consented to participate 
in the clinical research study. The term ‘Subject’ used in the eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
•
Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP), 
•
as defined by the International Council on Harmonisation (ICH)
•
in accordance with the ethical principles underlying European Union Directive 2001/20/EC
•
United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) 
•
applicable local requirements.
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the participant informed consent will receive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A breach of 
the conditions and principles of Good Clinical Practice (GCP) (occurring in any country) in 
connection with that trial or the protocol related to the trial which is likely to affect to a significant 
degree the safety or physical or mental integrity of 1 or more subjects of the trial or the scientific 
value of the trial.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant
recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The investigator 
or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product 
labeling information to be provided to subjects and any updates. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
Revised Protocol No.: 05
Date: 24-Jan-2019
66
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation or change will be submitted, as 
soon as possible to:
•
IRB/IEC
•
Regulatory Authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the participant volunteers to participate. 
Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample
informed consent form which will include all elements required by ICH, GCP and applicable
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Investigators must:
Revised Protocol No.: 05
Date: 24-Jan-2019
67
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 
•
Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details of the study.
•
Obtain an informed consent signed and personally dated by the participant or the participant's 
legally acceptable representative and by the person who conducted the informed consent 
discussion. 
•
Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects, prior to the beginning of the study, 
and after any revisions are completed for new information.
If informed consent is initially given by a participant’s legally acceptable representative or legal 
guardian, and the participant subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a person designated by the investigator, 
should fully inform the participant or the participant's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to participant records. 
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
Revised Protocol No.: 05
Date: 24-Jan-2019
68
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a Health Authority.
If
Then
Supplied by BMS (or its vendors):
Records or logs must comply with applicable 
regulations and guidelines and should include:
•
amount received and placed in storage 
area
•
amount currently in storage area
•
label identification number or batch 
number
•
amount dispensed to and returned by each 
participant, including unique participant
identifiers
•
amount transferred to another area/site for 
dispensing or storage
•
nonstudy disposition (e.g., lost, wasted) 
•
amount destroyed at study site, if 
applicable
•
amount returned to BMS
•
retain samples for 
bioavailability/bioequivalence, if 
applicable 
•
dates and initials of person responsible for 
Investigational Product 
dispensing/accountability, as per the 
Delegation of Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced from 
the sites stock or commercial supply, or a 
specialty pharmacy)
The 
investigator 
or 
designee 
accepts 
responsibility for documenting traceability and 
study treatment integrity in accordance with 
requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.
BMS or designee will provide forms to facilitate inventory control if the investigational site does
not have an established system that meets these requirements.
Revised Protocol No.: 05
Date: 24-Jan-2019
69
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillance form, respectively. If 
electronic SAE form is not available, a paper SAE form can be used.
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task.  The investigator must retain a copy of the CRFs including records of the changes and 
corrections.
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the BMS electronic data capture tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals
MONITORING
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable.
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee.
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
Revised Protocol No.: 05
Date: 24-Jan-2019
70
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vendor or sourced by the investigator) 
such as partially used study treatment containers, vials and syringes may be destroyed on site. 
If..
Then
Study treatments supplied by BMS (including 
its vendors
Any unused study treatments supplied by BMS 
can only be destroyed after being inspected and 
reconciled by the responsible Study Monitor 
unless study treatments containers must be 
immediately destroyed as required for safety, 
or to meet local regulations (eg, cytotoxics or 
biologics).
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the sites stock 
or 
commercial 
supply, 
or 
a 
specialty 
pharmacy)
It 
is 
the 
investigator’s 
or 
designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
•
On-site disposal practices must not expose humans to risks from the drug.
•
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
•
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
Revised Protocol No.: 05
Date: 24-Jan-2019
71
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
•
Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non- study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
CLINICAL STUDY REPORT AND PUBLICATIONS
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
•
Participant recruitment (eg, among the top quartile of enrollers)
•
Involvement in trial design
•
Other criteria (as determined by the study team)
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study site or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTAg.
Revised Protocol No.: 05
Date: 24-Jan-2019
72
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
APPENDIX 3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation participant administered study treatment
and that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
•
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant 
in the medical and scientific judgment of the investigator. Note that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term should be updated to be the 
diagnosis.
•
Exacerbation of a chronic or intermittent pre-existing condition including either an increase 
in frequency and/or intensity of the condition.
•
New conditions detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study.
•
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose, as a verbatim term (as reported by the 
investigator), should not be reported as an AE/SAE unless it is an intentional overdose taken 
with possible suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae and should specify “intentional overdose” as verbatim term.
Events NOT Meeting the AE Definition
•
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Revised Protocol No.: 05
Date: 24-Jan-2019
73
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met.
Revised Protocol No.: 05
Date: 24-Jan-2019
74
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below)
NOTE:
The following hospitalizations are not considered SAEs in BMS clinical studies: 
•
a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-threatening event)
•
elective surgery, planned prior to signing consent
•
admissions as per protocol for a planned medical/surgical procedure
•
routine health assessment requiring admission for baseline/trending of health status (e.g., 
routine colonoscopy)
•
medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
•
admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
•
admission for administration of anticancer therapy in the absence of any other SAEs (applies 
to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential drug induced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Revised Protocol No.: 05
Date: 24-Jan-2019
75
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
Pregnancy and potential drug induced liver injury (DILI) must follow the same transmission timing 
and processes to BMS as used for SAEs (see section 9.2.5 for reporting pregnancies).
EVALUATING AES AND SAES
Assessment of Causality
•
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.
•
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
•
The investigator will use clinical judgment to determine the relationship.
•
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.
•
The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
•
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to Sponsor. However, it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to Sponsor.
•
The investigator may change his/her opinion of causality in light of follow-up information 
and send a SAE follow-up report with the updated causality assessment.
•
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study treatment or if new 
information becomes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
Revised Protocol No.: 05
Date: 24-Jan-2019
76
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
REPORTING OF SAES TO SPONSOR OR DESIGNEE
•
SAEs, whether related or not related to study treatment, and pregnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
•
SAEs must be recorded on the SAE Report Form.
−
The required method for SAE data reporting is through the eCRF.
−
The paper SAE Report Form is only intended as a back-up option when the electronic 
data capture (EDC) system is unavailable/not functioning for transmission of the eCRF 
to BMS (or designee).
♦In this case, the paper form is transmitted via email or confirmed facsimile (fax) 
transmission
♦When paper forms are used, the original paper forms are to remain on site
•
Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission 
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact 
Information list
Revised Protocol No.: 05
Date: 24-Jan-2019
77
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
APPENDIX 4
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
•
Premenarchal
•
Premenopausal female with 1 of the following:
−
Documented hysterectomy
−
Documented bilateral salpingectomy
−
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•
Postmenopausal female
−
A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 
45 years in the absence of other biological or physiological causes. In addition, females 
under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their 
judgement in checking serum FSH levels. 
•
1 week minimum for vaginal hormonal products (rings, creams, gels)
•
4 week minimum for transdermal products
•
8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months. If the serum FSH 
level is > 40 mIU/ml at any time during the washout period, the woman can be considered 
postmenopausal.
Revised Protocol No.: 05
Date: 24-Jan-2019
78
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING 
POTENTIAL
One of the highly effective methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 1 days after the end of study treatment, 
plus 30 days
Local laws and regulations may require use of alternative and/or additional contraception methods.
Highly Effective Methods That Are User Independent
•
Nonhormonal IUDs, such as ParaGard ®
•
Bilateral tubal occlusion
•
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
•
Complete Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the participant.
•
Complete abstinence is an acceptable form of contraception for all study drugs and must be 
used throughout the duration of the study treatment (plus 5 half-lives of the investigational 
drug plus 30 days)
•
It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
•
WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 
•
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abstinence 
Unacceptable Methods of Contraception
•
Periodic abstinence (calendar, symptothermal, post-ovulation methods)
•
Withdrawal (coitus interruptus).
•
Spermicide only
•
Lactation amenorrhea method (LAM)
Revised Protocol No.: 05
Date: 24-Jan-2019
79
6.0
Approved
930114837
6.0
v


Clinical Protocol
CV013020
BMS-986231
HNO Donor
•
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
•
Hormonal methods of contraception including oral contraceptive pills containing combined 
estrogen + progesterone, vaginal ring, injectables, implants and intrauterine devices 
(IUDs)such as Mirena ®
•
Intrauterine hormone-releasing system (IUS)
•
Diaphragm with spermicide
•
Cervical cap with spermicide
•
Vaginal Sponge with spermicide
•
Male or female condom with or without spermicide*.  Male and female condoms cannot be 
used simultaneously
* REFERENCES FOR THE USE OF CONDOMS WITH SPERMICIDE.
Kestelman P. et. al., Efficacy of the Simultaneous Use of Condoms and Spermicides Family
Planning Perspectives.Vol 23 (5); October 1991.
Gabbay MB, Thomas J, Gibbs A, Hold P. A Randomized Crossover Trial of The Impact of
Additional Spermicide on Condom Failure Rates. Sex Transm Dis 2008; 35: 862-8.
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.
•
Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator.
•
Male participants are required to use a condom for study duration and until the end of relevant 
systemic exposure defined as 91 days after the end of treatment in the male participant.
•
Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 91 days after the end of 
treatment in the male participant.
•
Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 91 days after the end of treatment.
•
Refrain from donating sperm for the duration of the study treatment and for 91 days after the 
end of treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follow-up and Reporting
Revised Protocol No.: 05
Date: 24-Jan-2019
80
6.0
Approved
930114837
6.0
v









SAP_000.pdf: 
Official Title of Study: 
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 
Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart 
Failure and Impaired Systolic Function 
 
NCT Number: NCT03357731 
Document Date (Date in which document was last revised): December 6, 2017 








STATISTICAL ANALYSIS PLAN 
FOR 
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-
CONTROLLED, CROSS-OVER PHASE 2 STUDY OF CONTINUOUS 5-HOUR 
INTRAVENOUS INFUSIONS OF BMS-986231 IN PATIENTS WITH HEART FAILURE 
AND IMPAIRED SYSTOLIC FUNCTION 
PROTOCOL(S) CV013020 
VERSION # 1.0 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
2 
TABLE OF CONTENTS 
TABLE OF CONTENTS .................................................................................................................2 
 
 
2 
STUDY DESCRIPTION ..............................................................................................6 
2.1 
Study Design .................................................................................................................6 
2.2 
Treatment Assignment ..................................................................................................9 
2.3 
Blinding and Unblinding ..............................................................................................9 
2.4 
Protocol Amendments ................................................................................................10 
2.5 
Data Monitoring Committee and Other External Committees ...................................10 
3 
OBJECTIVES .............................................................................................................10 
3.1 
Primary .......................................................................................................................10 
3.2 
Secondary ...................................................................................................................10 
 
 
4 
ENDPOINTS ..............................................................................................................11 
4.1 
Primary Endpoints ......................................................................................................11 
4.2 
Secondary Endpoints ..................................................................................................11 
 
 
4.4 
Pharmacokinetic Endpoints ........................................................................................12 
5 
SAMPLE SIZE AND POWER ..................................................................................12 
6 
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS 
FOR ANALYSES .......................................................................................................13 
6.1 
Study Periods ..............................................................................................................13 
6.2 
Treatment Regimens ...................................................................................................13 
6.3 
Populations for Analyses ............................................................................................14 
7 
STATISTICAL ANALYSES .....................................................................................14 
7.1 
General Methods .........................................................................................................14 
7.2 
Study Conduct ............................................................................................................15 
7.3 
Study Population .........................................................................................................15 
7.4 
Extent of Exposure .....................................................................................................16 
7.5 
Efficacy .......................................................................................................................17 
7.5.1 
Primary Efficacy Analysis ..........................................................................................17 
7.5.2 
Secondary Efficacy Analysis .......................................................................................18 
7.6 
Safety ..........................................................................................................................18 
7.6.1 
Deaths .........................................................................................................................18 
7.6.2 
Serious Adverse Events ...............................................................................................19 
7.6.3 
Adverse Events ............................................................................................................19 
7.6.4 
Clinical Laboratory Evaluations ................................................................................20 
7.6.5 
ECG ............................................................................................................................23 
7.6.6 
Vital Signs ...................................................................................................................23 
7.6.7 
Physical Examination Findings ..................................................................................24 
7.6.8 
Daily Urinary Output .................................................................................................24 
7.6.9 
Oxygen Saturation ......................................................................................................24 
 
 
7.8 
Pharmacokinetics ........................................................................................................24 
8 
CONVENTIONS ........................................................................................................25 
8.1 
Safety Data Conventions ............................................................................................25 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
3 
8.2 
Baseline Measurements ..............................................................................................25 
8.3 
Multiple Measurements ..............................................................................................25 
8.4 
Pharmacokinetic Summaries ......................................................................................26 
9 
CONTENT OF REPORTS .........................................................................................26 
 
 
 
 
 




Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
.  
 
 Schedule of Analyses: 
There is no Data Monitoring Committee (DMC) planned for this study. Occurrence of significant 
safety events will be submitted for review to the independent DMC that monitors the ongoing 
phase 2b study, evaluating the safety, tolerability and effectiveness of BMS-986231 in a 
population of acute decompensated heart failure patients (NCT03016325)1. 
The final analysis will be performed following the database lock after all subjects have 
completed the study. No interim analyses will be performed 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
6 
2 
STUDY DESCRIPTION 
2.1 
Study Design 
This is a multi-center, randomized, cross-over, placebo and active-controlled, double-blind, 
study of continuous 5-hour intravenous (IV) infusions of BMS-986231 in patients with heart 
failure and reduced ejection fraction (HFrEF). The trial is designed to evaluate the effects of 
BMS-986231 on systolic and diastolic parameters measured by echocardiography. 
A cross-over design will be implemented in this trial; every subject will be exposed to each of 
the 3 interventions (BMS-986231, Nitroglycerin (NTG) and placebo) in 3 treatment periods. 
Each treatment period will include one intervention occurring via 5-hour infusion, followed by a 
washout period of at least 7 days, but no more than 4 weeks. 
42 study participants will be randomized to receive BMS-986231, NTG, and placebo, in one of 
the 6 possible sequences.  
NTG, BMS-986231 and placebo will be administered as a 5-hours infusion according to an 
uptitration schedule, which is achieved by an increase in the infusion flow rate. All three 
interventions (NTG, BMS-986231 and placebo) will have the same flow rate: 5 mL/H for 10 
min, followed by 10 mL/H for 10 minutes then 20 mL/H for the rest of the infusion. 
The corresponding doses of the active study medications will be: 
 NTG: 20 μg/min for 10 min, followed by 40 μg/min for 10 min, followed by 80 μg/min for 
the rest of the 5-hour infusion; 
 BMS-986231: 3 μg/kg/min for 10 min, followed by 6 μg/kg/min for 10 min, followed by 12 
μg/kg/min for the rest of the 5-hour infusion. 
In case of a decrease in systolic blood pressure, an algorithm will be used to down-titrate 
/interrupt or discontinue the study drug infusion (see protocol Section 7.4). 
The study design schematic is presented in Figure 2.1-1. 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
7 
Figure 2.1-1: 
Study Design 
 
 
 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
8 
Screening 
Screening for inclusion in the study will be performed up to 4 weeks before the first treatment 
day. Screening will assess the eligibility criteria including assessment of ejection fraction, 
suitability of echocardiography windows and image quality. After screening, study participants 
will be enrolled in the study according to their eligibility as per the inclusion and exclusion 
criteria, and will be randomized to 1 of the 6 sequences that will be conducted in parallel. 
Treatment day (Day 1 of each period) 
Study participants will be admitted to the study facility on the treatment day, which will be Day 
1 of each of the three periods. Assessment of vital signs and laboratory tests will be performed 
pre-dose. In each treatment day, blood pressure and heart rate should be within the inclusion / 
exclusion criteria limits, and no atrial fibrillation or atrial flutter should be present in order to 
start the study treatment. The study drug infusion could start without waiting for the results of 
the laboratory assessments done in the morning of the treatment day at the study facility if the 
following criteria are met: 
 The results of the laboratory assessment at screening / previous period are within ranges 
compatible with inclusion/exclusion criteria, 
 The study participant was medically stable without change in medication since the screening 
visit / previous period. 
If the laboratory tests (e.g. electrolytes, serum creatinine, eGFR, hemoglobin, transaminases) in 
the morning prior to the infusion are not within inclusion and exclusion criteria limits, the study 
drug will be discontinued after consultation with the medical monitor. The abnormalities should 
be corrected before the next treatment period. 
Physical examinations, vital sign measurements, 12-lead electrocardiograms (ECG), 
echocardiography, whole body bioimpedance and pulse wave analysis (non-invasive central 
aortic blood pressure) will be performed at selected times throughout the dosing interval. 
Participants will be closely monitored for adverse events throughout the study. Blood samples 
will also be collected at selected intervals after start of study drug administration for 
pharmacokinetic (PK) analysis. 
Discharge 
Study participants will remain in the study facility for approximately 3.5 hours post-dose and 
discharged on the same day, unless the investigator and the study team consider that an overnight 
stay is warranted. Same-day discharge is allowed if the following conditions are met: 
 in the opinion of the investigator an overnight stay is not warranted, 
 there is no hypotension after mobilization and 
 none of the following events occurred during the study drug infusion: prolonged 
hypotension, symptoms of hypotension, new onset of sustained arrhythmia requiring 
pharmacologic or other interventions, any other events of concern e.g. chest pain suggestive 
of ischemia. 
 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
9 
2.2 
Treatment Assignment 
This study will use Interactive Response Technology (IRT): All participants will be centrally 
randomized using an Interactive Response Technology (IRT). Subjects will be randomized using 
IRT in a 1:1:1:1:1:1 ratio to one of six sequences, as shown in Figure 2.1-1, with block size of 
six, to ensure the number of subjects randomized to each sequence remains balanced. 
Study treatment will be dispensed at the study visits as listed in Schedule of Activities (Protocol 
Section 2). 
Enrolled participants, including those not dosed, will be assigned sequential participant numbers 
starting with 00001, (e.g., 00001, 00002, 00003.... 00010). Those enrolled participants meeting 
inclusion and exclusion criteria will be eligible to be randomized. Randomization ID numbers 
will be assigned prior to dosing. Subjects who are re-enrolled (Protocol Section 6.4) will be 
assigned a new participant number. An estimated 52 subjects will be screened in order to 
randomize 42 subjects. Further details are provided in Section 5.  
Participants will not be replaced if they are discontinued from the study. 
2.3 
Blinding and Unblinding 
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual participant in which knowledge of 
the investigational product is critical to the participant's management, the blind for that 
participant may be broken by the investigator. The participant’s safety takes priority over any 
other considerations in determining if a treatment assignment should be unblinded. 
Before breaking the blind of an individual participant's treatment, the investigator should 
determine that the unblinded information is necessary, i.e., that it will alter the participant's 
immediate management. In many cases, particularly when the emergency is clearly not related to 
the investigational product, the problem may be properly managed by assuming that the 
participant is receiving active product. It is highly desirable that the decision to unblind treatment 
assignment be discussed with the Medical Monitor, but the investigator always has ultimate 
authority for the decision to unblind. The Principal Investigator should only call in for 
emergency unblinding AFTER the decision to discontinue the participant has been made. 
For this study, the method of unblinding for emergency purposes is via the Interactive Response 
Technology (IRT) system. For information on how to unblind in an emergency, consult the IRT 
manual. 
In cases of accidental unblinding, contact the Medical Monitor and ensure every attempt is made 
to preserve the blind. 
Any request to unblind a participant for non-emergency purposes should be discussed with the 
Medical Monitor. 
The Bioanalytical Sciences section or its designate may be unblinded to the randomized 
treatment assignments, in order to minimize unnecessary assays of samples from subject during 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
10 
the placebo treatment period. Likewise, the Biotransformation section or its designate may be 
unblinded, if metabolite profiling work is conducted. 
In certain circumstances, a pharmacokineticist or designate(s) in Clinical Pharmacology and 
Pharmacometrics, biostatistician(s) and programmer(s) at BMS, or designee, may be unblinded 
in order to prepare preliminary summaries of PK and safety data, as needed. These summaries 
will not reveal individual subjects’ treatment sequence assignments. 
 
2.4 
Protocol Amendments 
This statistical analysis plan (SAP) is based on the revised protocol version 02, which 
incorporates Amendment 02, dated 01-Sep-2017. 
2.5 
Data Monitoring Committee and Other External Committees 
There is no Data Monitoring Committee (DMC) planned for this study. The occurrence of 
significant safety events will be submitted for review to the independent DMC that monitors the 
ongoing phase 2b study CV013011, evaluating the safety, tolerability and effectiveness of BMS-
986231 in a population of acute decompensated heart failure patients (NCT03016325). 
The executive committee will be a small body comprised of academic leaders. The executive 
committee will provide advice on overall design, study endpoints and recommendations for 
study sites, and will review results from final analyses with Sponsor. 
3 
OBJECTIVES 
3.1 
Primary 
The primary objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) 
systolic function by SVI assessed by echocardiography compared to placebo. 
3.2 
Secondary 
Secondary objectives include the following: 
 Evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by SVI 
assessed by echocardiography compared to nitroglycerin (NTG). 
 Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic 
indices compared to placebo and NTG: 
 LV ejection fraction 
 Mean LV power index 
 Diastolic function 
 LV global longitudinal strain 
 
 
 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
ENDPOINTS 
4.1 
Primary Endpoints 
The primary endpoint is the Mean SVI derived from the velocity time integral at the left ventricular 
outflow tract (LVOT VTI) at the end of the 5-hours infusion of BMS-986231, versus placebo. 
4.2 
Secondary Endpoints 
Secondary endpoints include the following: 
 Mean SVI derived from LVOT VTI at the end of the 5-hours infusion of BMS-986231, 
versus NTG. 
 Mean LVEF, computed by Simpson’s method at the end of the 5-hours infusion of BMS-
986231, versus placebo and NTG. 
 Mean cardiac power index at the end of the 5-hours infusion of BMS-986231, versus placebo 
and NTG. 
 Mean Diastolic indices: E/A, annular e’ velocity, and E/e’ ratio at the end of the 5-hours 
infusion of BMS-986231, versus placebo and NTG. 
 Mean LV global longitudinal strain, computed using STE at the end of the 5-hours infusion 
of BMS-986231, versus placebo and NTG. 
 
 
 
 
 
 
 
 
 
 
 
 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 
Pharmacokinetic Endpoints 
 Pharmacokinetic endpoints include the Plasma concentrations of BMS-986231 and its 
metabolites 
5 
SAMPLE SIZE AND POWER 
In a review of stroke volumes and SVIs from the literature, baseline SVI generally ranged from 
30-40 mL/m², with inter-individual standard deviation (SD) of approximately 25 – 35% of the 
mean. Likewise, SV values generally ranged from 50-70 mL, with inter-individual SD of 
approximately 25 – 35% of the mean. Results from these studies also suggest intra-individual 
correlations in the range of 0.6 – 0.8. 
Sample size calculations assume baseline SVI of approximately 30 mL/m², with placebo values 
consistent with baseline, an increase of 15% from baseline, relative to placebo, as meaningful 
(e.g. 4.5 mL/m²), an inter-individual SD of 10 mL/m², and intra-individual correlations for the 
difference between placebo and HNO of 0.7. Using these assumptions, approximately 36 
subjects with data from treatment periods being compared will be required to achieve a power of 
90%, with a type I error probability of 0.05 (2-sided). In order to address the potential for 
missing data arising from dropout, an allowance of 15% subjects will be included, with a 
resulting target sample size of 42 subjects to be randomized. An estimated 52 subjects will be 
screened, in order to randomize 42 subjects. Sample sizes are calculated based on method IV 
from Mehrotra2, which compares post baseline values, adjusting for the differences in the 
baseline value. The blinded SVI data will be reviewed after 50% of the planned treated subjects 
have completed treatment. BMS will consider re-estimating the sample size based on the 
observed SD. The review of SVI data will be repeated if necessary.  


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
13 
6 
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS FOR 
ANALYSES 
6.1 
Study Periods  
Screening for inclusion in the study will be performed up to 4 weeks before the first treatment 
day. After screening, study participants will be enrolled in the study according to their eligibility 
as per the inclusion and exclusion criteria, and will be randomized to 1 of the 6 sequences that 
will be conducted in parallel. 
Each sequence has 3 periods. Study participants will be admitted to the study facility on the 
treatment day, which will be the Day 1 of each of the three periods. Study participants will 
remain in the study facility for approximately 3.5 hours post-dose and discharged on the same 
day, unless the investigator and the study team consider that an overnight stay is warranted. The 
treatment day of period 1 and period 2 are followed by a washout period of at least 7 days but no 
more than 4 weeks.  
6.2 
Treatment Regimens 
The selection and timing of dose for each participant is as follows: 
Table 5.2-1: 
Selection and Timing of Dose 
Study Treatment Unit dose strength(s)/Dosage level(s) 
Dosage 
formulation 
Frequency of 
Administratio
n 
Route 
of 
Administration 
BMS-986231 
3 μg/kg/min for 10 min (5 mL/H) 
6 μg/kg/min for 10 min (10 mL/H) 
12 μg/kg/min for the rest of the 5-hour 
infusion (20 mL/H) 
Single infusion IV 
Nitroglycerin 
20 μg/min for 10 min (5 mL/H) 
40 μg/min for 10 min (10 mL/H) 
80 μg/min for the rest of the 5-hour 
infusion (20 mL/H) 
Single infusion IV 
Placebo* 
5 mL/H for 10 min 
10 mL/H for 10 min 
Single infusion IV 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
14 
Table 5.2-1: 
Selection and Timing of Dose 
Study Treatment Unit dose strength(s)/Dosage level(s) 
Dosage 
formulation 
Frequency of 
Administratio
n 
Route 
of 
Administration 
20 mL/H for the rest of the 5-hour 
infusion 
* Placebo will be a solution of 5% dextrose (D5W) that will be locally supplied by the sites. 
6.3 
Populations for Analyses 
The following populations will be used for the analyses: 
 The Enrolled Population will consist of all subjects who sign informed consent 
 The Randomized Population will consist of all randomized subjects who have started study 
drug infusion in at least one treatment period. This is also known as the Intent to Treat (ITT) 
population. Data in this data set will be analyzed based on randomized treatments in each 
period. 
 The Safety Population will consist of all subjects who take at least 1 dose of double-blind 
study treatment. Participants will be included in the treatment group they received in each 
period.  
 The Pharmacokinetic analysis dataset (PK Population) will consist of all subjects who 
receive BMS-986231 and have at least one post dose PK sample. Additionally, the 
Evaluable PK Population is defined as subjects who have adequate PK profiles. 
7 
STATISTICAL ANALYSES 
SAS® version 9.2 or higher will be used for statistical analyses, tabulations and graphical 
presentations. S-Plus® may be also used for graphical presentations.  
7.1 
General Methods 
Descriptive summaries will be presented for continuous variables using number of subjects (N), 
mean, standard deviation (SD), median, minimum and maximum. 
Descriptive summaries for categorical variables will utilize counts and percentages. Several 
analyses noted in subsequent sections will present 95% confidence intervals (CIs), but no pre-
specified significance testing will be included. 
In general, continuous variables will be analyzed using a mixed-effect model with sequence, 
treatment period, and treatment, and the difference in the treatment period baselines as a 
covariate. From the statistical modeling, the means, standard errors, and 2-sided 95% confidence 
intervals for the difference between BMS-986231 and the other treatment group will be 
presented. The analyses for efficacy and exploratory endpoints will use a nominal level of 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
15 
α=0.05 for inference with no multiplicity adjustment. The nominal p-value for comparing two 
treatments will be provided as well. 
Adverse events and medical history will be coded according to the most recent Medical 
Dictionary for Regulatory Activities (MedDRA) version. Previous and concomitant medications 
will be coded using the WHO Drug Dictionary. 
For analyses involving baseline, the baseline value is defined by the last value prior to the start of 
infusion for a specified period, unless otherwise noted. 
7.2 
Study Conduct 
Protocol deviations identified as significant will be captured in a trial management system and 
reported in the CSR. Relevant protocol deviations are those that are programmable and could 
potentially affect the interpretability of the study results. The following protocol deviations will 
be defined as relevant protocol deviations and listed:  
 Error in treatment assignment resulting in a subject being dosed with an incorrect treatment 
 Systolic blood pressure (SBP) < 115 mm Hg at screening or pre-randomization 
 Violation of inclusion criterion 2 (b): Subjects do not have heart failure with reduced ejection 
fraction or have no LVEF on echocardiogram of 40% or less. 
 Violation of exclusion criterion 1 (a): Subjects have Systolic blood pressure (SBP) < 115 mm 
Hg at screening or pre-randomization. 
 Violation of exclusion criterion 1 (b): Subjects have heart rate < 50 beats per minute (bpm) 
or > 90 bpm at screening or pre-randomization. 
 Violation of exclusion criterion 3 (a): Subjects have  treatment with oral phosphodiesterase 
type 5 (PDE5) inhibitor sildenafil, vardenafil or avanafil within 24 hours of study drug 
infusion or treated with tadalafil within 4 days of study drug infusion. 
 Violation of exclusion criterion 4 (a): Subjects have estimated glomerular filtration rate 
(eGFR) < 15 ml/min/1.73 m2.  
7.3 
Study Population 
1.1.1 Subject Disposition  
Subject disposition will be listed. Summary tables reflecting the number of subjects who are 
enrolled, who are randomized, and reasons for not being randomized, will be presented as 
overall.  
The number of subjects who do not complete each treatment of 5 hours infusion, both overall 
and according to reasons for discontinuation from the treatment, will be summarized for safety 
population. Subjects who have temporary interruption or down-titration of study drug but do not 
discontinue permanently will be analyzed as completing the treatment. The number of subjects 
who do not complete the study phase, both overall and according to reasons for not completing, 
will be summarized for safety population, as overall and by treatment group. 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
16 
1.1.2 Demographics and Baseline Characteristics 
Frequency distributions and summary statistics for demographic and baseline variables will be 
presented for all enrolled subjects. Demographic variables to be summarized include: age, 
gender, race, ethnicity, and region. 
Baseline variables to be summarized include the following: 
 Physical measurements (height, body weight, body mass index)  
 Vital signs (body temperature, respiratory rate, systolic and diastolic blood pressure and heart 
rate) 
1.1.3 Physical Measurements 
Physical measurements such as body weight and height will be summarized by nominal visit for 
the safety population, as overall and by treatment group. Measurements will also be listed for all 
treated subjects. 
1.1.4 Medical History and Previous Medications 
Medical history and previous medications taken prior to dosing will be listed for the safety 
population.  
7.4 
Extent of Exposure 
At any time during the administration of study drug, the study drug infusion must be 
discontinued if an adverse event or any other safety issue suggests it is not in the patient’s best 
interest to continue to receive study drug. 
The investigator has the option to adjust the study drug dosage level downward by 50%, 
interrupt, or discontinue the study drug infusion in patients that develop hypotension, or if the 
patient experiences symptomatic hypotension that is not easily tolerated, as follows 
 Study drug reduction: Study drug is decreased by 50% if SBP decreases to levels <90 mmHg 
but ≥80 mmHg. The dose cannot be subsequently increased. 
 Study drug interruption: Study drug is interrupted for 1 hour if SBP decreases to <80 mmHg 
or symptoms of low blood pressure occur within the first 4 hours of infusion. If the SBP is 
105 mmHg after one hour interruption, the study drug could be resumed at 50 % of the 
dose to complete 5-hours of effective study drug infusion. 
 Study drug discontinuation: Study drug will be permanently discontinued if SBP remains < 
105 mmHg after 1 hour interruption or if SBP decreases to levels <80 mmHg or symptoms of 
low blood pressure occur after 4 hours of infusion. 
End of infusion procedures should be done as soon as possible after interruption or 
discontinuation of the study drug. If an infusion in a given period is discontinued, patients 
remain eligible to complete subsequent periods. 
Study drug administration and randomization schedule will be documented as per subject 
listings. The number and percentage of subjects with dose interruptions, dose reductions, and 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
17 
dosing discontinuations will also be summarized and listed by treatment group for the safety 
population. 
Any non-study medications taken by subjects, any conducted non-study medical treatment 
procedures, and any utilized non-study diagnostic procedures will also be listed. 
 
7.5 
Efficacy 
 
7.5.1 
Primary Efficacy Analysis 
SVI derived from the velocity time integral at the left ventricular outflow tract (LVOT VTI) at 
the end of the 5-hours infusion of treatment will be summarized descriptively for all randomized 
subjects by treatment group.  
SVI will be assessed using a contrast comparing placebo and BMS-986231. We follow the linear 
model proposed by Jemielita et al3, which includes sequence and treatment and the difference in 
the treatment period baselines as a covariate. Jemielita et al demonstrated that modelling certain 
linear combinations of baseline values as covariates increases the power of the test for a 
difference in outcomes by treatment.  In this study, the difference in baseline values among the 
treatments being compared will be considered according to this strategy. They further 
demonstrated that the model will give equivalent inference as in an ordinary least squares (OLS) 
model for difference of treatment effects, under the assumption of unstructured covariance 
structure. The Kenward-Roger approximation for the degrees of freedom will be specified for the 
model. 
Estimation of the variance covariance will be based on unstructured (UN) R matrix assuming no 
common variances or covariances. 
Let   
Xik=(XiPk, XiNk, XiTk)T 
Yik=(YiPk, YiNk, YiTk)T 
be distinct 3-length vectors of baseline SVI and end of infusion SVI, respectively. The subscript 
i=1,...6 indexes the sequences, and P, N, T represent Placebo, NTG and BMS 986231. Moreover, 
k=1,...7 indexes subject k in sequence i.  
We fit the following linear mixed model: 
(YiTk-YiPk)|(XiTk-XiPk)=(T-P)+(iT-iP)+(T-P)(XiTk-XiPk)+(iTk-iPk), 
where T-P  is the difference of treatment effects of BMS-986231 and Placebo, iT-iP is the 
difference of treatment effect of BMS-986231 and Placebo within sequence i, T-P is the 
regression coefficient, and iTk-iPk is the variance term.  


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
18 
The hypotheses of interest are: 
H0: T-P =0 
HA:T-P 0. 
The mean SVI at the end of 5-hour infusion of BMS-986231 versus Placebo, corresponding 
standard error, p value, and 95% confidence interval will be calculated by the below SAS code 
and presented. Considering the sample size is small, the Kenward-Roger degree of freedom is 
used to adjust the standard error of treatment effect.  
PROC MIXED DATA=EXAMPLE_DATA; 
CLASS sequence; 
MODEL ydiff_TP = sequence xdiff_TP / DDFM=KENWARDROGER; 
ESTIMATE 'tau_T - tau_P' intercept 1 xdiff_TP / CL; 
run; 
SVI will be summarized and listed for all randomized subjects as overall and by treatment.  
7.5.2 
Secondary Efficacy Analysis 
Using the same model as in the primary analysis, this analysis will be repeated for the secondary 
endpoints listed below and will also examine the comparison of  BMS-986231 vs NTG in 
addition to BMS-986231 vs Placebo. 
  Mean SVI derived from LVOT VTI at the end of the 5-hours infusion of BMS-986231, 
versus NTG. 
 Mean LVEF, computed by Simpson’s method at the end of the 5-hours infusion of BMS-
986231, versus placebo and NTG. 
 Mean cardiac power index (CPI) at the end of the 5-hours infusion of BMS-986231, versus 
placebo and NTG. Cardiac power index is calculated by the following equation: CPI [W/m2 ] 
= mean aortic pressure [mmHg] cardiac output [L/min] / body surface area [m2 ] 0.0022.  
 Mean Diastolic indices: E/A, annular e’ velocity, and E/e’ ratio at the end of the 5-hours 
infusion of BMS-986231, versus placebo and NTG. 
 Mean LV global longitudinal strain, computed using STE at the end of the 5-hours infusion 
of BMS-986231, versus placebo and NTG. 
The secondary endpoints will be summarized and listed for all randomized subjects as overall 
and by treatment. 
7.6 
Safety 
All safety presentations will be based on the Safety Population. 
7.6.1 
Deaths 
All reported deaths after a subject is enrolled (i.e., has signed the informed consent) will be listed 
separately by subject. 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
19 
7.6.2 
Serious Adverse Events 
All reported serious adverse events (SAEs) will be listed by System Organ Class (SOCs) and 
Preferred Terms (PTs) for all safety population subjects. SAEs must be collected from the date of 
informed consent and will be assessed up to 30 days after the end of infusion of the last period. 
7.6.3 
Adverse Events 
All AEs will be coded and grouped into PT by SOC, using current version of Medical Dictionary 
for Regulatory Activities (MedDRA). All recorded AEs will be summarized and listed by SOCs, 
PTs and treatment group. 
Non-serious AEs with onset time from the start of study drug infusion, until 24 hours after end of 
infusion in each treatment period of dosing in each period will be included in the summary 
tables. Events will be assigned to the study treatment administered to the subject. The proportion 
of subjects having an adverse event will be calculated as the number of subjects experiencing the 
event, divided by the total number of subjects receiving study treatment. 
All AE listings will indicate the unique subject identifier, age, gender, current treatment, the date 
and time of onset, the date and time of resolution, day of onset relative to the start of treatment, 
action taken, investigator’s assessment of severity and relationship to study drug. Additional 
listings will be provided for adverse events leading to discontinuation and adverse events without 
recorded resolution. Summaries of adverse events will include adverse events, adverse events by 
intensity and adverse events by relationship.   
Where a subject has the same adverse event, based on preferred terminology, reported multiple 
times in a single analysis period, the subject will only be counted once at the preferred 
terminology level in adverse event frequency tables. 
Where a subject has multiple adverse events within the same system organ class in a single 
analysis period, the subject will only be counted once at the system organ class level in adverse 
event frequency tables. 
When a subject has the same adverse event, based on preferred terminology, reported multiple 
times in a single analysis period, the following criteria, in order of precedence, will be used to 
select the event to be included in summary tables: 
 Relationship to study medication 
 Intensity of event 
 Onset date and time 
When reporting adverse events by intensity, in addition to providing a summary table based on 
the event selection criteria detailed above, summary tables will also be provided based on the 
most intense event  during the analysis period - independent of relationship to study medication. 
For these tables, the following criteria, in order of precedence, will be used to select the event to 
be included in summary tables: 
 Intensity of event 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
20 
 Onset date and time 
Subjects will only be counted once in the ‘Total’ at their maximum intensity, regardless of SOC 
or PT. 
7.6.4 
Clinical Laboratory Evaluations 
The results of all protocol-specified clinical laboratory tests will be listed. Scheduled laboratory 
measurements will be summarized by treatment and scheduled time points for each laboratory 
test. 
The criteria used for classifying laboratory test results as markedly abnormal will be listed.  
Laboratory results for subjects with any marked laboratory abnormality (scheduled and 
unscheduled) will be listed. This listing will include all observations for the specific laboratory 
test and subject, not only the marked laboratory abnormalities. The frequency of subjects with 
any marked laboratory abnormality as well as hematology, serum chemistry, and urinalysis 
marked abnormalities, based on pre-specified criteria (see Table 6.6.2.4-1), will be presented.  
Troponin T will be summarized descriptively by treatment for each time point, as well as change 
from baseline. Geometric mean and coefficient of variation (%CV) will also be presented for the 
original values and percent of baseline.  
Table 6.6.2.4-1: 
Laboratory MA Criteria 
Parameter 
Test 
Code 
Direction 
of Change 
MA Criteria in US Standard Units 
(apply to labs collected after baseline 
only) 
MA Criteria in SI Units 
(apply to labs collected after baseline 
only) 
HEMATOLOGY 
Hemoglobin 
HB 
Low only 
> 2 g/dl decrease compared to pre-dose 
or  Value  8 g/dl  
> 20 g/l decrease compared to pre-dose 
or  Value  80 g/l  
Hematocrit 
HCT 
Low only 
< 0.75  pre-dose  
< 0.75  pre-dose  
Erythrocytes 
RBC 
Low only 
< 0.75  pre-dose  
< 0.75  pre-dose  
Platelet Count 
PLAT 
Low Only 
< 100,000/mm3 (or < 100 109 cells/L)  
< 100 109 cells/L  
Leukocytes 
WBC 
Low/High 
< 0.75  LLN or > 1.25  ULN, or 
if pre-dose < LLN then use < 0.8  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.2  pre-
dose or < LLN 
< 0.75  LLN or > 1.25  ULN, or 
if pre-dose < LLN then use < 0.8  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.2  pre-
dose or < LLN 
Neutrophils 
(absolute) 
NEUTA 
Low Only 
< 1.0  103 cells/L 
< 1.0 109 cells/L 
LIVER/KIDNEY 
Alkaline 
Phosphatase  
ALP 
High only 
> 2  ULN 
> 2  ULN 
Aspartate 
AST 
High only 
> 3  ULN, > 5  ULN, > 10  ULN 
> 3  ULN, > 5  ULN, > 10  ULN 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
21 
Table 6.6.2.4-1: 
Laboratory MA Criteria 
Parameter 
Test 
Code 
Direction 
of Change 
MA Criteria in US Standard Units 
(apply to labs collected after baseline 
only) 
MA Criteria in SI Units 
(apply to labs collected after baseline 
only) 
Aminotransferase 
Alanine 
Aminotransferase 
ALT 
High only 
> 3  ULN, > 5  ULN, > 10  ULN 
> 3  ULN, > 5  ULN, > 10  ULN 
Bilirubin, Total 
TBILI 
High only 
> 2  ULN 
> 2  ULN 
Blood Urea 
Nitrogen 
BUN 
High only 
>2  ULN  
>2  ULN  
Serum Creatinine 
CREAT 
High only 
> 1.5  ULN 
> 1.5  ULN 
ELECTROLYTES 
Sodium, Serum 
NA 
Low/High 
< 0.95  LLN or > 1.05 ULN, or 
if pre-dose < LLN then use < 0.95  pre-
dose or >ULN 
if pre-dose > ULN then use > 1.05  pre-
dose or < LLN 
< 0.95  LLN or > 1.05 ULN, or 
if pre-dose < LLN then use < 0.95  pre-
dose or >ULN 
if pre-dose > ULN then use > 1.05  pre-
dose or < LLN 
Potassium, Serum 
K 
Low/High 
< 0.9 LLN or > 1.1 ULN, or 
if pre-dose < LLN then use < 0.9  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.1  pre-
dose or < LLN 
< 0.9 LLN or > 1.1 ULN, or 
if pre-dose < LLN then use < 0.9  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.1  pre-
dose or < LLN 
Chloride, Serum 
CL 
Low/High 
< 0.9  LLN OR > 1.1  ULN, or 
if pre-dose < LLN then use < 0.9  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.1  pre-
dose or < LLN 
< 0.9  LLN OR > 1.1  ULN, or 
if pre-dose < LLN then use < 0.9  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.1  pre-
dose or < LLN 
Calcium, Total 
CA 
Low/High 
< 0.8  LLN or > 1.2  ULN, or 
if pre-dose < LLN then use < 0.75  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.25  pre-
dose or < LLN 
< 0.8  LLN or > 1.2  ULN, or 
if pre-dose < LLN then use < 0.75  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.25  pre-
dose or < LLN 
Bicarbonate 
HCO3 
Low/High 
< 0.75  LLN or > 1.25  ULN, or 
if pre-dose < LLN then use < 0.75  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.25  pre-
dose or < LLN 
< 0.75  LLN or > 1.25  ULN, or 
if pre-dose < LLN then use < 0.75  pre-
dose or > ULN 
if pre-dose > ULN then use > 1.25  pre-
dose or < LLN 
OTHER CHEMISTRY 
Creatine Kinase 
CK 
High only 
> 5  ULN 
> 5  ULN  


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
22 
Table 6.6.2.4-1: 
Laboratory MA Criteria 
Parameter 
Test 
Code 
Direction 
of Change 
MA Criteria in US Standard Units 
(apply to labs collected after baseline 
only) 
MA Criteria in SI Units 
(apply to labs collected after baseline 
only) 
Total Protein 
TPRO 
Low/High 
< 0.9  LLN or > 1.1  ULN, or 
if pre-dose < LLN then use 0.9  pre-
dose or > ULN 
if pre-dose > ULN then use 1.1   pre-
dose or < LLN 
< 0.9  LLN or > 1.1  ULN, or 
if pre-dose < LLN then use 0.9  pre-
dose or > ULN 
if pre-dose > ULN then use 1.1   pre-
dose or < LLN 
Glucose, 
Serum 
Fasting 
GLUCF 
Low/High 
< 0.8  LLN or > 1.5  ULN, or 
if pre-dose < LLN then use < 0.8  pre-
dose or > ULN 
if pre-dose > ULN then use > 2.0  pre-
dose or <LLN 
< 0.8  LLN or > 1.5  ULN, or 
if pre-dose < LLN then use < 0.8  pre-
dose or > ULN 
if pre-dose > ULN then use > 2.0  pre-
dose or <LLN 
Uric Acid 
URIC 
High only 
> 1.5  ULN, or 
if pre-dose > ULN then use > 2  pre-
dose 
> 1.5  ULN, or 
if pre-dose > ULN then use > 2  pre-
dose 
Albumin 
 
Low only 
≤ 2 g/dL  
≤ 20 g/L  
URINALYSIS 
Protein, Urine 
UPRO 
High only 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
Blood, Urine 
UBLD 
High only 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
Leukocyte 
Esterase, Urine 
ULEUK 
High only 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
RBC, Urine 
URBC 
High only 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
23 
Table 6.6.2.4-1: 
Laboratory MA Criteria 
Parameter 
Test 
Code 
Direction 
of Change 
MA Criteria in US Standard Units 
(apply to labs collected after baseline 
only) 
MA Criteria in SI Units 
(apply to labs collected after baseline 
only) 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
WBC, Urine 
UWBC 
High only 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
If missing pre-dose then use  2, or 
if value  4, or 
if pre-dose = 0 or 0.5 then use  2, or 
if pre-dose = 1 then use  3, or 
if pre-dose = 2 or 3 then use  4 
 
7.6.5 
ECG 
All recorded ECGs (heart rate (HR), QT (QT, Bazett’s corrected QT [QTcB], Fridericia's 
corrected QT [QTcF]), PR and QRS intervals) will be listed. 
Summaries of ECG parameters (heart rate (HR), QT (QT, QTcF), PR and QRS intervals) will be 
tabulated by time point and treatment. Summaries of ECG parameters will include change from 
baseline at list of time points. 
If QTcF is not available in the database, QTcF will be calculated using the reported uncorrected 
QT Interval and Heart Rate, and the following formula:  


3
/
1
60
RATE
HEART
QT
QTcF 
 
 
Subjects with ECG intervals outside of a pre-specified range will also be listed. 
The following criteria will be used to determine ECG results that are outside of a pre-specified 
range: 
PR (msec): 
Value > 200 
QRS (msec): 
Value > 120 
QT (msec): 
Value > 500 or change from baseline > 30 
QTcF (msec): 
Value > 450 or change from baseline > 30 
 
7.6.6 
Vital Signs 
Vital sign measurements will be summarized by treatment group at each scheduled time point 
using descriptive statistics. 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
24 
7.6.7 
Physical Examination Findings 
All physical examination abnormal findings will be listed per subject.   
7.6.8 
Daily Urinary Output 
Urinary output is collected from start of infusion to 3 hours after end of infusion in each 
treatment period. Daily urinary output will be summarized descriptively for all safety population 
by treatment for each time point.  
7.6.9 
Oxygen Saturation 
Peripheral Oxygen Saturation is collected prior to the infusion and after end of infusion in each 
treatment period. Oxygen Saturation will be summarized descriptively for all safety population 
by treatment for each time point as well as change from baseline.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
7.8 
Pharmacokinetics 
Blood samples will be collected from all subjects at pre-dose, 0.5, 1 and 4.5 hours during 
infusion and 2 hours after end of infusion and plasma concentrations will be measured using 
LC-MS. In addition, a PK sample will be collected from the subject when the dose is lowered 
due to a safety event and also at time of early discontinuation of study drug. Pharmacokinetic 
parameters for BMS-986231 and BMT-284730 and other metabolites (e.g., BMT-279554 and 
CAR-000463) will be estimated as appropriate. The plasma concentration data may also be used 
to conduct population pharmacokinetic analysis and exposure-response analysis with select 
efficacy and safety endpoints. Results of the population pharmacokinetic and exposure-response 
analysis will be reported in a separate report. 
The PK population will be used for all listings. The Evaluable PK population will be used for 
summaries and statistical analyses. Geometric mean and coefficient of variation (%CV) will also 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
25 
be presented for sample plasma concentration-time data. Analysis will include all analyte data in 
the PK dataset for BMS-986231 and metabolites of BMS-986231. 
Subject plasma concentration-time profiles will be listed and summarized by treatment and 
nominal collection time for each analyte. Plots of mean (+SD) plasma concentration profiles 
versus time will be presented for each analyte, and all treatments will be superimposed on the 
same plot. Concentration at the end of infusion will also be summarized by treatment, which is 
the concentration at hour 5 for subjects completing 5 hours infusion and the concentration 
collected at early discontinuation for subjects not completing 5 hours infusion. The PK samples 
collected when the dose is lowered due to a safety event will be listed. 
 
8 
CONVENTIONS 
8.1 
Safety Data Conventions 
Except as noted in Section 7.6, safety data will be handled according to the BMS safety data 
conventions4. This document includes descriptions on how to analyze AE data as well as how to 
handle partial dates, missing dates, and unknown end dates when analyzing safety data. If onset 
time of AEs is missing or incomplete, the onset date of AEs will be used to determine if the AEs 
will be included in the AE summary tables as follows. 
 Non-serious AEs will be included in summary tables if the onset date/time is on or after the 
start of the study drug infusion until 24 hours after endo f infusion in each treatment period 
of dosing.  
 Serious AEs will be included in summary tables if the onset date/time is on or after the start 
date of study drug infusion until 30 days after the end of infusion of the last period. 
8.2 
Baseline Measurements 
For analyses involving baseline, the baseline value is defined by the last value prior to the start of 
infusion, unless otherwise noted. 
When there is a missing baseline assessment it will not be imputed. 
8.3 
Multiple Measurements 
For longitudinal summaries of data, if there are multiple records within the same Hour ranges, 
then the value closest to the time of the planned time points is selected unless specified 
otherwise.  
Laboratory Measurements 
For tabulations of changes from baseline or shift analyses, if multiple laboratory measurements 
are obtained within the same nominal visit, then the measurement obtained on the day closest to 
the target day for that nominal visit will be used; in the case of a tie, the measurement obtained 
on the earlier day will be used in the analyses. 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
26 
For tabulations of incidence of marked abnormalities (e.g. ALT > 3xULN), if multiple laboratory 
measurements are obtained within the same nominal visit, then the worst measurement within the 
nominal visit window nominal visit will be used. 
Vital Signs and ECGs 
If multiple vital sign or ECG measurements are obtained within the same nominal visit, then the 
measurement obtained on the day closest to the target day for that nominal visit will be used; in 
the case of a tie, the measurement obtained on the earlier day will be used in the analyses. 
8.4 
Pharmacokinetic Summaries 
In-text Tables 
For in-text pharmacokinetic tables, coefficient of variation (%CV) will be reported as integers. 
For other statistics except for standard deviations, values of 100 or higher will be presented as 
integers, values of 10 - <100 will be displayed to one decimal place, and values of 1 - < 10 will 
be displayed to two decimal places. Values less than 1 will be displayed to three decimal places.  
Ratios will also be displayed to three decimal places. Standard deviations will be reported to a 
precision of 1 decimal place more than the mean. 
Handling of Non-Quantifiable Concentrations 
For the summaries of plasma concentration-time data, concentrations that are less than the lower 
limit of quantification (LLOQ) should be displayed as “< LLOQ” in the listings and be treated as 
missing in summary tables and plots.   
All available plasma concentration-time data will be included in the PK data set and listed 
accordingly. 
Treatment of Outliers 
Individual plasma concentrations, if deemed to be anomalous, may be excluded from the analysis 
following a review of available documentation (e.g., bioanalytical report, clinical data). Any 
such exclusion will be clearly listed in the study report along with justification for exclusion. 
Entire plasma concentration-time profiles for a subject may be excluded following review of 
available documentation (e.g., bioanalytical report, clinical data). However, results of analysis 
with and without the excluded profiles may be presented in the study report. Any such exclusion 
will be clearly listed in the study report along with justification for exclusion. 
PK Exclusions5 
PK Analysis, Reporting, and Exclusion criteria should follow the BMS PK Harmonization 
document Version 3.0.  
9 
CONTENT OF REPORTS 
Statistical components for the clinical study report will be based on the content of this statistical 
analysis plan (SAP). Details of the tables, listings, and figures to be prepared for interim analyses 
and the final CSR will be included in a study-specific Data Presentation Plan (DPP). 


Statistical Analysis Plan 
CV013020 
BMS-986231 
pro-drug of HNO 
 
27